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ABSTRACT 
Back ground and literature review 
Introduction 
Acute upper gastrointestinal bleeding is a common cause of emergency hospital 
admission. It is also not uncommon in patients already in hospital. 
111 
The bulk of severe morbidity and mortality occurs in patients with recurrent bleeding 
or significant comorbid illness. The use non-steroidal anti-inflammatory drugs 
(NSAID), which is more common in the elderly, more than doubles the mortality 
associated with peptic ulcer complications. Endoscopy and endotherapy have 
improved outcome in patients with continued or recurrent bleeding. 
Clinical Predictors of Outcome 
Despite improved technology in the management of upper gastrointestinal bleeding 
(UGIB), mortality has remained high. This has been attributed to the increase in the 
population of elderly people who tend to have other underlying diseases leading to the 
high mortality rate. From international literature, mortality varies from 4-10%. Most 
of the reports reflect mortality around 8%. A local retrospective study by Van 
Stiegmann et. al. ( 1983) on patients with bleeding peptic ulcer had an overall 
mortality of 5.4 %, and mortality of 9.8% in those treated surgically. 
Ideally to avoid waste of resources and time, emergency endoscopy should primarily 
be considered in relatively few patients at risk of further haemorrhage. In this class of 
patients endoscopy is used not only for diagnosis but also for endoscopic treatment to 
control massive ulcer bleeding. This approach is worthy of consideration in a 
"resource poor" environment. 
Most previous studies have employed endoscopic criteria for identifying patients at 
high risk of poor outcome. These data are not available at the time of admission. 
This is therefore not helpful in the triage of patients prior to endoscopy. 
Groote Schuur Hospital (location for the current study) has experienced a significant 
staff cutback over the past 5 years. Few of our regional hospitals and none of our 
primary health care facilities have endoscopy facilities and endoscopic expertise is 
similarly limited. Given the pressures on the limited endoscopy services, there is a 
need for guidelines for the referral of patients to centres with these facilities. 
There is a possibility that the number of potential referrals of patients with upper 
gastrointestinal bleeding (UGIB) will increase as the primary health care services 
improve, a rational review of criteria for referral appeared timely. There would be 
need to triage patients into: 
i). those who must have endoscopy urgently and 
ii). those who could be safely referred for elective endoscopy. 
lV 
Most previous studies have looked at predictors of adverse outcome. To our 
knowledge no study has been done in South Africa to determine clinical predictors of 
good outcome prior to endoscopy, that would help determine patients who would 
recover uneventfully without urgent endoscopy. 
Study Rationale 
Given the scarcity of both endoscopy resources and of information for the triage of 
patients who would recover uneventfully following UGIB without urgent endoscopy 
in our setting, this study set out to answer the question: 
Is it possible to identify clinical criteria that will predict patients with UGIB in whom 
endoscopy could be safely deferred? 
OBJECTIVES: 
1. To identify clinical criteria that predict uneventful recovery. 
V 
2. To determine the accuracy of individual symptoms and signs or combinations . 
of symptoms or signs at the time of presentation in predicting uneventful 
recovery. 
Study population and Methods 
Study design and study setting: 
The design was a prospective, descriptive, cross sectional study with an analytical 
component. 
The study was conducted at Groote Schuur Hospital (GSH), which is a tertiary 
referral teaching hospital with 14 70 beds. It is affiliated to the University of Cape 
Town. 
Subjects: 
Two hundred consecutive patients over the age of 12 years, presenting with 
haematemesis and/or melaena but without history of varices or gastrointestinal 
neoplasm were included into the study over a 10 month period (1997-1998). The 
median age was 57.5 years (range 43.7-71.4 years). There were 112 males and 78 
females. Predictor variables prior to endoscopy were collected and all patients 
underwent endoscopy. 
Independent variables (potential predictors) and dependent variable 
The clinical predictors of interest were pre-syncope or syncope, use of non-steroidal 
anti-inflammatory drugs (NSAID), salicylates, or warfarin, history of ingestion of 
alcohol , history of previous peptic ulcer disease, haemoglobin concentration, pulse, 
systolic blood pressure, postural hypotension, age and comorbidity. 
Vl 
The study outcome criterion ( dependent variable) was good outcome (i.e. no blood 
transfusion or endoscopic therapy or surgery, and alive one month after presentation). 
The relative risk of good outcome for each predictor variable was calculated. 
Multiple stepwise logistic regression analysis was used to identify the combinations 
of variables that best predicted outcome. Sensitivity, specificity, predictive values 
and likelihood ratios were calculated for these combinations of variables. 
Results 
Of the 200 patients, 102 (51%) had blood transfusion, 35 (17.5%) patients had 
endoscopic therapy and 8 (4%) underwent surgery, 4 (50%) had surgery for a 
malignant ulcer and 4 (50%) for benign peptic ulcer disease. The total mortality rate 
was 6.5%. 
Eighty ( 40%) of the patients had a good outcome (i.e. no blood transfusion or 
endoscopic therapy or surgery, and alive one month after presentation). 
Vll 
Haemoglobin concentration greater than 10 g/dl (OR 25.5; 95% CI, 8.9-74.8; p = 
<0.001), absence of melaena (OR 4.8; 95% CI, 1.8-12.9; p =0.002) and absence of 
history of syncope (OR 4.0; 95%CI, 1.7-9.5; p = 0.002) were independent predictors 
of good outcome. A combination of all three variables had the best association with 
good outcome when compared to a single variable or a combination of any two of 
these variables. The model with all three variables had sensitivity for good outcome 
of34% (27-40%), specificity of98% (95-100%), positive predictive value of 90% 
(86-94%) and negative predictive value of 69% (62-75%). The likelihood ratio for a 
positive test was 13.5 (5.3-54) and the likelihood ratio for a negative test was 0.68 
(0.57-0.79). 
Of the 200 patients, 30 (15%) had the combination for the prediction rule 
(haemoglobin greater than 10 g/dl, no melaena and no syncope). These patients 
would have not been referred for urgent endoscopy. Three (10%) of these i.e.1.5% of 
the total sample had a poor outcome. They all required sclerotherapy to control 
haemorrhage and none of them died. 
Conclusion 
Thus, in this study population with a 40% prevalence of good outcome, haemoglobin 
greater than I Og/dl, absence of syncope and absence of history of melaena were 
independent predictors of good outcome. The best prediction rule for good outcome 
was the combination of all the 3 variables. This had sensitivity for good outcome of 
34% and specificity of 98%, the likelihood ratio for positive and negative test of 13 .5 
and 0.68 respectively. These test characteristics indicate that the test was accurate at 
excluding poor outcome, which is a priority in the clinical context. The test was not 
accurate at predicting good outcome. The clinical implications of these findings are 
Vlll 
that there would be a 15% reduction in unnecessary endoscopies with 5% or less of 
the patients with poor outcome sent home without endoscopic examination. 
The findings of this study may have clinical relevance especially in under-resourced 
healthcare environment in which we practice. However the test needs validation 
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CHAPTER 1 INTRODUCTION 
CHAPTER 1 INTRODUCTION 
1.1 Background and Literature Review 
Acute upper gastrointestinal bleeding is a common cause of emergency hospital 
admission. A study from the United States of America reported approximately 300,000 
hospitalisations with health expenditure in excess of $2.5 billion per year for acute upper 
gastrointestinal bleeding (Cutler 1981 , Gostout 1998). It is also not uncommon in 
patients already in hospital (Johnston 1973). 
Despite improved technology in the management of upper GIT bleeding (UGIB), 
mortality has remained high. This has been attributed to the increase in the population of 
elderly people who tend to have other underlying diseases leading to the high mortality 
rate. From international literature, mortality varies from 4-10%. Most of the reports 
reflect mortality around 8% (Mueller 1994, Clements 1991 , Katschinski 1994, Steffes 
1992, Sugawa 1990, Silverstein 1981, Turner 1991 ). The bulk of severe morbidity and 
mortality occurs in patients with recurrent bleeding or significant comorbid illness 
(Terdiman 1998, Jaramillo 1994, Zimmerman! 995). 
The use non-steroidal anti-inflammatory drugs (NSAID), which is more common in the 
elderly, more than doubles the mortality associated with peptic ulcer complications 
(Armstrong 1987). A local retrospective study by Van Stiegmann et al. (1983) on 
patients with bleeding peptic ulcer had an overall mortality of 5.4 %, and mortality of 
9.8% in those treated surgically. 
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1.1.1 Incidence and epidemiology of UGIB 
Earlier local studies have reported occurrence of peptic ulcer disease rather than that of 
UGIB. In South Africa these have shown a rising trend in the proportion of peptic ulcer 
disease, which is the most common cause of UGIB. The proportion rose from 0.9 per 
1000 hospital admissions between 1943-1948 (Charlewood and Frylinck 1951) to 4.5 per 
1000 in 1977 (Segal et. al.). In the study by Segal et al., 28% of the patients with peptic 
ulcer disease presented with haematemesis and/or melaena. A 4-year study ( 1978-1981) 
at Groote Schuur hospital had an average of 437.5 admission per year for UGIB (Van 
Stiegmann et. al.1983). The total number of admissions per year for the period was not 
stated. 
Earlier European series indicate that between 40 and 120 persons per 100 000 population 
are admitted to hospital with haematemesis and/or melaena (Schiller et.al.1970, Johnson 
et al. 1973 ). The incidence in Denmark in 1987 was 90 per 100 000 adults per year 
(Wara 1987). Two large population-based studies (Longstreth 1995, Rockall 1995) 
showed the yearly incidence of upper gastrointestinal bleeding requiring hospitalisation 
to be about 100 per 100 000 adults. The incidence varies with age; rising from 23 in 
those aged under 30 to 485 in those aged over 75 years (Rockall 1995). It was twice as 
high in men as in women (Rockall 1995, Longstreth 1995). The increasing age of the 
population presenting with UGIB that has been documented by many researchers is a 
reflection of the increasing age of the general population. In the United Kingdom a study 
by Johnson et al. (1973) of 817 patients found that 49% were over the age of 60. In the 
study of Rockall et al ( 1995) of 4185 patients, the proportion of patients over the age of 
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60 was 68%. Over the same period ( 1941-1991) the age structure of the population had 
changed considerably with the proportion of those aged over 60 years increasing from 
15% in 1941 to 21% in 1991 (Rockall 1995). 
1.1.2 Causes of upper gastrointestinal haemorrhage 
3 
Peptic ulcer remains the commonest cause of acute non-variceal upper gastrointestinal 
haemorrhage. Ulcer bleeding accounts for 50% of the cases, although the incidence may 
be expected to fall with wider use of Helicobacter pylori eradication therapy and as 
COX2-specific non-steroidal anti-inflammatory drugs are developed (Palmer 2000). The 
proportion of variceal bleeding in a study population is dependent on the population 
under study. A study done on a population with a high incidence of alcoholism showed a 
greater proportion of varices (22%) and erosive disease (24%) in comparison to other 
series (Sugawa et al. 1990). In the United Kingdom varices have been reported to 
represent 2-4% of the patients presenting with upper gastrointestinal bleeding (UGIB) 
(Report of a Joint Working Group 1992). The other commonly reported causes are 
oesophagitis (10%), gastritis (3%), Mallory-Weiss tear (3%) and malignancy (2%) (Wara 
' 
1987). In the local study (Van Stiegman et al. 1983), of 1750 patients presenting with 
UGIB 55% had peptic ulcer disease as the source of their bleed. The source of bleeding 
in the remaining 45% was not stated. 
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1.1.3 Risk Factors for Gastrointestinal Bleeding and Peptic ulcer bleeding 
• Nonsteroidal anti-inflammatory drugs (NSAID) and salicylates 
Significant association between use ofNSAID and salicylates and upper gastrointestinal 
bleeding from peptic ulcers, oesophagitis and gastric erosions has been reported in 
4 
several studies (Sommerville et. al. 1986, Levy et. al. 1988, Holvoet et al. 1991 ). In some 
series over one third of all haemorrhages from peptic ulcers can be attributed to NSAID 
or aspirin use (Holvoet et.al. 1991 ). 
NSAIDs cause damage to the gastroduodenal mucosa via several mechanisms, including 
the topical irritant effect to the epithelium, impairment of the barrier properties of the 
mucosa, suppression of prostaglandin synthesis through a systemic effect which is 
independent of route of administration (prostaglandins play a role in modulating mucosa! 
defence), reduction of the mucosa! blood flow and interference with the repair of 
superficial injury (Wallace 2000). 
Administration of NSAIDs as suppositories, has been shown to increase the risk of upper 
gastrointestinal bleeding because of the higher dosages administered by this route. Thus 
Henry et al. ( 1993) in their case-control study found NS AID by the rectal route to have 
an odds ratio of 11.4 compared to 2.3 by oral route. 
Carson et al. (1987) and Henry et al. (1993) in their case-control studies found that the 
increased risk of upper gastrointestinal bleeding in patients taking NSAID followed a 
linear dose-response relationship. 
Weil et al. ( 1995) in a case-control study investigated the association of aspirin with 
gastrointestinal bleeding in a study involving 1121 patients presenting with UGIB and 
1126 hospital and 989 community matched controls. The odds ratio for aspirin was dose 
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dependent: 2.3 for 75mg (CI 1.2-4.4), 3.2 for 150 mg (CI 1.7-6.5) and 3.9 for 300 mg (CI 
2.5-6.3). The risk was higher with regular aspirin (OR= 4, CI 2.8-5 .8) than for enteric-
coated aspirin (OR=l.1 , CI 0.4-3 .3). Short-term use for less than a month was associated 
with highest risk (OR =9 .2, CI 2.3-160.1 ). Laszlo et al. ( 1998) found that the 
combination of over the counter aspirin or NSAID plus alcohol was associated with the 
highest odds ratio (OR 4.47, 95% CI 2.73 to 7.32) for bleeding when compared to 
controls or any of these factors alone. 
• Alcohol 
Alcohol causes injury to gastric mucosa by interrupting the gastric mucosa barrier, thus 
permitting back-diffusion of hydrogen ions. This results in cellular injury and damage to 
small blood vessels and thus mucosa! damage and superficial ulceration (Friedman 1998). 
The severity of mucosa! damage is directly related to the local ethanol concentration and 
length of exposure (Domschke et al. 1984). Although there are no controlled studies to 
show that alcohol causes clinically significant UGIB, acute haemorrhagic gastritis 
accounts for 25% of cases of major haemorrhage in alcoholics compared to 5% in non-
alcoholics (Domschke et al. 1984). The combination of alcohol and another "barrier 
breaker" e.g. salicylates increases the risk of gastrointestinal blood loss (Kaufman et al. 
1999). 
Despite the common belief that alcohol increases the risk of peptic ulcer disease, the 
evidence for this is still conflicting. Some studies have shown no relationship between 
intake of alcohol and increased risk of developing peptic ulcer disease (Friedman 1974, 
Ivey.1981) 
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• Helicobacter pylori (in relation to peptic ulcer disease) 
Case-control studies have shown reduced rate of recurrent bleeding in patients who had 
received ulcer therapy that included eradication therapy for H pylori (Jaspersen 1995, 
Rokkas 1995, Santander 1995). The findings in these studies were similar, with rebleed 
rates of 27% and 33% in controls and none in those who received eradication therapy. 
The longest follow-up period for these studies has been two and half years hence long-
term effects of H pylori eradication cannot be defined (Rollhauser 1997). Contrary to 
this, Pilotto et al. (1997) in a case-control study on elderly patients presenting with UGIB 
found an inverse relationship between H pylori-positivity and bleeding in patients with 
gastric erosions and a lower overall risk for bleeding in H pylori-positive NSAID users 
than H pylori-negative NSAID users. H Pylori infection was thought to increase gastric 
prostaglandin synthesis, which has a protective mechanism on the mucosa, resulting in a 
protective effect against UGIB in the elderly who normally have age related decreases in 
prostaglandin E2. 
• Gastric acid and Pepsin (in relation to peptic ulcer disease) 
In the past ideas concerning the pathogenesis of peptic ulcer disease, which count for half 
the admissions for acute UGIB, focused on the role of acid and pepsin. Medical therapy 
for peptic ulcer has centred on inhibition of gastric acid secretion. Gastrin is the most 
potent stimulant of gastric acid secretion. The final step in the secretion of the hydrogen 
ion is accomplished by an H\ K+-ATPase 'proton pump' located in the structure of the 
parietal cell. Proton pump inhibitors (omeprazole, lansoprazole and pantoprazole) are 
CHAPTER 1 INTRODUCTION 
specific inhibitors of the H\ K+ -ATPase 'proton pump', and potent inhibitors of gastric 
acid secretion. These drugs are substituted benzimidazoles that bind to the proton pump 
and irreversibly inactivate it (Friedman 1998). 
7 
Gastric mucosa also contains large amounts of histamine in cytoplasmic granules of mast 
cells and enterochromaffin-like cells. Histamine is an important stimulant of gastric acid. 
Recognition of the role of histamine in acid secretion led to the discovery of Histamine2 
receptor antagonists (e.g. cimetidine, ranitidine, famotidine and nizatidine). 
1.1.4 CLINICAL PREDICTORS OF OUTCOME 
Most previous studies have employed endoscopic criteria for identifying patients at high 
risk of poor outcome (Wara 1985; Storey 1981; Longstreth 1995; Rockall 1996). These 
data are not available at the time of admission. This is therefore not helpful in the triage 
of patients prior to endoscopy. 
It is commonplace that manifestations of acute UGIB result in reflex interventions and 
care driven by established practice patterns. Ideally, to avoid waste ofresources and 
time, it would be helpful to identify those patients in whom endoscopy could be delayed 
without deleterious outcome. Emergency endoscopy should primarily be considered in 
patients at risk of further haemorrhage. In this class of patients endoscopy is used not 
only for diagnosis but also for endoscopic treatment to control massive ulcer bleeding 
(Wara 1985). This approach is worthy of consideration in a "resource poor" 
environment. 
The major task in patients with upper gastrointestinal haemorrhage is to select those 
patients with bleeding requiring haemostatic intervention. The widely used endpoints in 
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patients with bleeding ulcers are the number of units of blood transfused, the need for 
urgent surgery and death. The determinants of these endpoints are the magnitude of 
initial bleeding episode, whether bleeding persists or recurs, patient's age and overall 
health (Braniski 1990; Armstrong 1987; Schiller 1970). 
Clinical markers that indicate a high risk of further haemorrhage and therefore poor 
outcome include haemodynamic instability on presentation, bleeding ·manifested as 
repeated red haematemesis, haematochezia (passage of red blood per rectum) and failure 
to respond to resuscitative measures. Haemodynamic assessment includes measures of 
blood pressure, pulse and their postural changes (Laine 1994). 
8 
Contrary to studies that emphasise the importance of clinical predictors, W ara et al. 
(1987), reported that bleeding pattern before admission and other clinical factors were not 
reliable predictors of major haemorrhage in a number of studies. 
Research and debate on important factors influencing the outcome of acute upper 
gastrointestinal haemorrhage began in the 1940' s (Rockall 1996). Risk factors associated 
with both re-bleeding and death are well known. However, there has been no agreement 
on a set of risk factors as different researchers have put a different emphasis on each of 
these according to their experiences (Northfield 1971; Mayberry 1981 ; Katschinski 
1994). Age, comorbidity, shock, admission haemoglobin values, presentation (either 
haematemesis, melaena or both), ulcer type, ulcer size, stigmata ofrecent haemorrhage 
(visible vessel in an ulcer bed, ooze, fresh clot), and transfusion requirement have all 
been described as significant risk factors for further haemorrhage and death. The risk of 
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rebleed and death is well known to be related not to an individual factor but to many 
factors which tend to interact with each other (Rockall 1996). 
There is still controversy as to the significance of these clinical factors and endoscopic 
findings in predicting outcome. The problem with comparing findings of different 
studies is that most of the studies done have been small (Rockall 1995, Turner 1991 ). 
Turner et al. reported a variation in mortality in upper gastrointestinal bleeding due to 
variation in sample size with small studies having sample sizes ranging from 66 to 148 
patients and larger studies with samples of 387-1427 patients. 
On the small samples, it has been impossible to assess the impact of individual factors , 
while controlling for confounding effects from other factors on the outcome of bleeding. 
The other problem in comparing different series is the variable patient selection criteria. 
This introduces selection bias in the study results (Turner 1991 ). This could explain the 
variability in the clinical predictions of adverse outcome in the different studies. 
Another source of discrepancy is the follow up period. Earlier studies have followed up 
patients only up to the date of discharge. It has been shown in some studies that death 
from upper gastrointestinal bleeding does not occur only during the first few days 
following the bleed but is evenly distributed over the one month following the episode 
(Hasselgren 1998, Provenzale 1987). 
Furthermore, some studies have been done retrospectively. Retrospective studies have a 
problem of bias as the data collected were not intended for the study and record retrieval 
may be incomplete (Rockall 1995). 
Some studies have validated their findings while others have not. 
9 
CHAPTER 1 INTRODUCTION 10 
• Identification of low-risk patients presenting with UGIB 
Until recently, no study had attempted to devise a simple and therefore clinically useful 
risk scoring system that would be readily available to the clinician for categorising 
patients by risk. As junior doctors manage most cases of acute upper gastrointestinal 
bleeding, a risk scoring system would be a useful aid to patient selection (Rockall 1996). 
Of the studies that have investigated predictors of outcome, a large number 
have looked at predictors of adverse outcome (rebleed, death, and surgery). Very few 
studies have looked at predictors of good outcome. Even then, most of these studies have 
included endoscopic findings in their decision criteria (Rockall 1996, Longstreth 1995, 
Longstreth 1998, Lai 1997). Endoscopy facilities are not readily available to "resource 
poor" communities. The clinical factors in some scoring systems are cumulatively of 
greater predictive value than endoscopic findings if one removes patients with advanced 
liver disease, varices and suspected variceal bleeding, a group at greater risk of adverse 
outcome (Goustoutl 998). 
Except for studies by Bordley et al. (1985) and Kollef et al (1995), most previous studies 
selecting patients at low risk of adverse outcome have included endoscopic features in 
their patient selection. Bordley et al. ( 1985) concluded that patients at low risk of poor 
outcome, i.e. with none of the following: death, emergency surgery, re bleed or significant 
complications were unlikely to benefit from early endoscopy and could be managed as 
out-patients. The predictors of good outcome in this study were: age less than 75 years; 
no unstable comorbid illness; no ascites on physical examination; normal prothrombin 
time and within one hour after presentation, a systolic blood pressure of 100 mm Hg or 
more and nasal gastric aspirate free of fresh blood. Caution must be exercised in 
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adopting the results of this study because of the small sample size (see table 1), as chance 
plays a major role in such situations. 
Kollef et al. (1995) found from their study that patients classified as being at low risk of 
adverse outcome had significantly lower rates ofre-bleed (3.6% versus 22.5%; p = 0.022) 
and had lower mortality (0.0% versus 21.3%; p = 0.008) compared to patients classified 
as being at high risk. Low risk patients were defined according to the following criteria: 
(a) haemodynamically stable before ICU admission (i.e. mean arterial pressure of >60 
mm Hg and systolic blood pressure > 100 mm Hg); (b) not requiring the use of 
vasopressors; ( c) not having evidence of other organ failure requiring ICU admission; and 
( d) not having evidence of active, ongoing gastrointestinal haemorrhage at the time of 
triage determination. The results of this study are not applicable to all categories of 
patients presenting with upper gastrointestinal bleeding as the study population included 
only patients managed in the intensive care unit. These patients would have had quite a 
significant bleed and had invasive procedures such as intra-arterial blood pressure 
readings prior to triage. These facilities are not available at the local primary and most 
secondary level hospitals. 
A summary of studies that investigated predictors of good outcome or low risk of adverse 
outcome are shown in table 1. 
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Table 1: Studies of predictors of good outcome or low risk of adverse outcome 
Studyffype/Sample Endpoint Scope validated Significant variables 
Rockall 1996 Low risk (no Yes Yes Age (0-2), Shock (0-2), Comorbid (0-3), 
Prospective rebleed, no Diagnosis (0-2), SRH (0-2) 
multicentre ( 4185). death) Score $ 2 = low risk 
Risk score 
Bordley et. al. 1985 * Good No Yes ( 111 patients Age < 75, no comorbid, no ascites, normal PT, 
Retrospective ( 162) outcome prospectively) BP > I 00, NG aspirate no blood 
Longstreth et. al. Out patient Yes 1% No SRH, no varices or portal HGP, no 
1998 treatment. hospitalisation, debilitation, no orthostatic signs, no severe liver 
176 selected using Risk of 1 % rebleed, no disease or concomitant disease, no anticoagulants 
pre-selected rebleed or death or coagulopathy, no fresh haematemesis or 
guidelines death melaena, Hb >8 g/dl 
Lai et. al. Low risk of Yes Yes (75 patients Age < 60, stable vital signs, no SRH, no serious 
Retrospective re-bleed with DU) comorbidity 
Pre-selected criteria No re-bleed in 
(72 patients) all 
Ko lief MH et. al. Low risk of No Yes Mean arterial BP < 60 mmHg, no vasopressors 
1995 rebleed or Used pre- used, BP > I 00 mm Hg, no unstable comorbid 
Prospective ( I 08 ICU death selected criteria 
patients) 
* None of these features: death , emergency surgery, rebleed, significant complications. Scope= endoscopy 
SRH= endoscopic stigmata of recent haemorrhage, PT= prothrombin time, BP= blood pressure in mm Hg 
NG= nasogastric tube, Hb = haemoglobin, DU = duodenal ulcer, ICU = intensive care unit, HGP = 
hypertensive gastropathy. 
• Studies that used risk scores or other pre-determined criteria to categorise 
patients into high or low-risk of adverse outcome. 
A number of studies derived a risk score or guidelines that were used to classify patients 
into high or low risk of poor outcome following upper gastrointestinal haemorrhage 
(Rockall 1996, Provenzale 1987, Bordley 1985, Kollef. 1995, Kollef 1997, Morgan 1988, 
De Dombal 1986, Longstreth 1998). 
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1. Studies including endoscopy features as a method of triage 
In Britain, Rockall et al. ( 1996) assigned a weighed "risk score" from five variables to 
predict outcome in patients with UGIB. The British scoring system was drawn from a 
two-phased questionnaire type prospective population based study designed to establish 
the relative risk for mortality after acute UGIB. The variables were: (I) age in years ( < 
60 = 0, 60-79 = 1 and ~ 80 = 2), (2) shock (systolic blood pressure ~ 100 and pulse < 100 
beats/min = 0, systolic blood pressure ~ 100 and pulse ~ 100 beats/min = 1, systolic 
blood pressure < 100 = 2), (3) comorbidity (none = 0, cardiac failure, ischaemic heart 
disease, or other major comorbidity = 2, and renal failure, liver failure or disseminated 
malignancy = 3 ), ( 4) endoscopic diagnosis (Mallory- Weiss tear, no lesion found at 
endoscopy, and no endoscopic stigmata of recent haemorrhage (SRH) = 0, all other 
diagnoses = 1, and malignancy of the upper gastrointestinal tract= 2) and (5) major 
stigmata of recent haemorrhage (SRH) (none or dark spot only= 0, blood in upper 
gastrointestinal tract, adherent clot, visible vessel or spurting vessel = 2). Not included as 
risk factors were haemoglobin, gender, use of certain drugs (NSAID and anticoagulants, 
and presentation other than shock, e.g. haematemasis and /or melaena. A patient scored a 
maximum of 7 points prior to endoscopy and a maximum of 11 points after endoscopy. 
They concluded that patients with a score of~ 2 should be considered for early discharge 
or be treated as out-patients as rebleeding occurs in less than 5% and mortality is virtually 
zero. The British investigators concluded that their risk score could identify 15% of all 
cases of acute UGIB on presentation and 26% of all cases after endoscopy who were at 
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low risk of recurrent bleeding and death. The study results are not applicable to our needs 
as the risk score is inclusive of endoscopic diagnosis. 
Longstreth and Feitelberg (1998) utilised pre-set guidelines (see table 1) derived from 
their earlier study (Longstreth et. al 1995) to select patients for outpatient treatment. An 
important addition to their criteria was the availability of adequate social support at 
home. Patients with liver disease, varices or portal hypertensive gasfropathy were 
excluded for their known increased risk of adverse outcome. With these guidelines 
hospitalisation was required in I%, recurrent bleeding occurred in 1 % and there were no 
deaths during 5 to 27 months period of follow up of the selected patients. These authors 
applied the British "risk score," mentioned above to their patient population. One third of 
the patients who were successfully managed as outpatients had scores greater than two 
and would have been assessed as high risk by the British system. The guidelines from 
the study by Longstreth and Feitelbergjust as the risk score from the British study would 
not be applicable to our needs as the decision criteria included endoscopic features . 
Hay et al. (1996), from literature review, derived clinical guidelines in form of a scoring 
system using 4 variables. These were scored as: (a) haemodynamics (stable= 0 points, 
intermediate = I , unstable =2), (b) time from bleeding (> 48 hours = 0, < 48 hours = I, in 
hospital= 2), (c) comorbidity (::51 = 0, 2 = 1, 3 = 2, ~ 4 = 3) and (d) upper gastrointestinal 
endoscopy (0-4 points, with stigmata ofrecent haemorrhage scoring 3 points, and 
persistent UGIB, varices and UGI malignancy scoring 4 points). The hypothesis of the 
study was that the proposed guidelines would reduce length of hospital stay for low-risk 
patients with acute UGIB while maintaining or improving quality of care compared to the 
standard practice. A recommendation for continued hospital stay was given for a total 
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score of ~3. The scoring system was applied retrospectively on 500 patients with UGIB, 
and it was noted that 70% of their patients achieved low-risk status and could therefore 
undergo early discharge with a complication rate of 0.6%; 95% CI, 0.07-2.1, and no 
worsening of quality of care. Complications were defined as in-hospital death, 
emergency surgery, recurrent bleeding, decompensated chronic or new unstable 
comorbid illness and readmission within 30 days. An acceptable risk of recurrent 
bleeding was 3% or less. Ninety-four percent of recurrent bleeding and 92% of 
complications occurred within 72 hours. Although their focus was on reducing hospital 
stay, the ability to identify low risk patient group would be a move towards outpatient 
management. Of note as in the fore-mentioned studies, is the use of urgent endoscopy as 
a method of triage. 
11. Studies that did not include endoscopy features as a method of triage 
Provenzale et al. (1987) investigated predictors of outcome prior to endoscopy. The 
predictors used and their scores were: (a) melaena (absent= 0, present= -1) as melaena 
was a negative predictor of mortality; (b) haematochezia ( absent = 0, present = 1 ); ( c) 
drop in haematocrit of 5% ( absent = 0, present = 1 ); ( d) level of systolic blood pressure in 
mm Hg (>100 = 0, 90-99 = 1, 80-89 = 2, <80 =3); (e) chronic renal disease (absent= O 
present= 1 ), (f) liver disease: (i) encephalopathy (absent= 0, present= 1 ), (ii) spider 
naevi (absent= 0, present= 1), (iii) prothrombin time in seconds (<12 = 0, 12-15 = 1, 
> 15 = 2) and (g) duration of the bleed in hours (>12 = 0, 3-12 = 1, <3 = 2). The 
minimum score was minus 1 and maximum score was 12. They concluded that patients 
with scores~ 2 were less likely to die while those with ·a score> 6 were at a high risk of 
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dying. The patients at high risk of dying would be candidates for aggressive management 
and therapeutic endoscopy. This study did not state the management plan for patients 
with scores between 3 and 5. Management decisions would presumably be at the 
discretion of the attending physician. 
Kollef et al. ( 1997) reported that patients at high risk had significantly greater rates of in-
hospital complications (RR 2.47; 95% CI, 1.38-4.44, p <0.001) at Barnes hospital and RR 
8.94; 95% CI, 3.92-20.49; p <0.001 at Jewish Hospital. The classification tool they used 
was called BLEED standing for: on going bleeding, low systolic blood pressure, elevated 
prothrombin time, erratic mental state, unstable comorbid disease. This classification 
tool would not be applicable to our needs, as some laboratory investigations such as 
prothrombin time are not readily available in all centres. 
Morgan et al. (1988) used a computer programme to categorise patients. According to 
presenting symptoms (age, liver disease, heart failure, alcohol history, drug history, 
continuing bleeding, confusion, dehydration, jaundice, ascites, haemoglobin 
concentration and systolic BP), patients were classified by a computer programme into 
very high, high, medium, low and very low risk categories of adverse outcome. Rate of 
re bleed decreased with reduction in computer-predicted risk of rebleed. In the very high-
risk category, 60% of patients re-bled and 32% died while in the low risk group only 4% 
re-bled and there were no deaths. The variables associated with adverse outcome are as 
shown in the table 2. The problem with computer aided analysis is the assumption that 
every centre would have access to a computer. 
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De Dombal et al. (1986) conducted a similar study and their findings were similar to 
those of Morgan et al. except that De Bomba! included endoscopic features in 
categorising their patients. 
Table 2. Studies using risk score or other pre-determined criteria to categorise 
patients into high or low-risk of adverse outcome. 
Studyffype/Sample Endpoint Scope Validated Significant variables 
Rockall et. al. 1996 Low risk (no Yes Yes Age (0-2), Shock (0-2), Comorbid (0-3), 
Prospective multicentre (4185). rebleed, no Diagnosis (0-2), SRH (0-2) 
Risk score death) Score ~ = low risk 
Provenzale et. al. 1987 Mortality No Yes Liver disease, Renal disease, continued 
retrospective (153) (I 04 patients) bleeding 
Risk score Score ~ 2 low risk 
Score > 6 high risk 
Kollef et. al. 1997 High risk of No Yes Continued bleeding, BP < 100 mm Hg, 
Prospective ( 465) rebleed, Used PT > 1.2, Erratic mental state, Unstable 
surgery, predetermined comorbid 
death classification 
tool 
De Dombal et. al. 1986 High risk of Yes No Age > 60, History of heart or liver disease? 
Prospective (4010, O.M.G.E rebleed or confusion, dehydration, jaundice, ascites, 
Survey) death Hb < IO g/dl, BP <90 mm Hg, bleeding 
from cancer or varices 
Morgan et. al. 1988 Risk of Re- No Yes Age > 60, liver disease, jaundice, ascites, 
Prospective (2623) bleed, Used prognostic heart failure, BP < 90 mm Hg, confusion, 
mortality factors from a dehydration, Hb < IO g/dl 
previous study 
(1434 patients) 
Longstreth et. al. 1995 Low risk Yes Yes Age < 60, Hb > IO g/dl, no alcoholism, no 
Retrospective (933) patients 141 patients syncope or pre-syncope, no unstable 
(78 for outpatient treatment, ( out-patient (34 outpatient comorbidity, BP > I 00 mmHg, pulse < 
no complication) treatment) treatment), I 00, no orthostatic signs, no SRH 
I re-bleed 
SRH= endoscopic stigmata of recent haemorrhage, PT= prothrombin time, BP= blood pressure, Hb = 
haemoglobin, O.M.G.E = Organisation Mondiale De Gastroenterologie (World organisation of 
gastroenterology) . Scope=endoscopy 
• Local studies 
To our knowledge no study has been done in Cape Town to determine clinical predictors 
of good outcome prior to endoscopy, that would help determine patients who would 
recover uneventfully without urgent endoscopy. 
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Van Stiegman et al. (1983) retrospectively analysed 967 patients admitted to Groote 
Schuur hospital (Cape Town) with bleeding peptic ulcer between 1978-1981 . This study 
looked at predictors of mortality, which included endoscopic features. The predictors of 
mortality were identified to be age> 50 years, shock (systolic blood pressure <90 mm Hg 
re-bleed, comorbidity, multiple or stomal ulcers and transfusion> 10 units. Like most 
international studies, the results of this study are not applicable to our current needs as it 
includes endoscopic features and there was only one endpoint, mortality. This study also 
has the above-noted problems associated with retrospective studies. 
1.1.5 Why the need to have predictors of good outcome? 
Of principal concern is the safety of patients who would to be discharged from primary 
and secondary health care facilities for deferred endoscopy examination. Reducing the 
number of urgent endoscopies at the expense of patients' safety would be deleterious. 
There is a need to isolate predictors of good outcome with a discriminatory ability to 
accurately classify patients that would be safely discharged on medical therapy without 
prior endoscopy and recover without any adverse event. Most studies have looked at 
predictors of adverse outcome. One could argue that we should implement the opposite 
of the predictors from these studies if we require good outcome measures. This is not 
possible for the reasons previously stated, such as the use of different endpoints in these 
studies to the current study. Studies that devised risk scores had groups of patients that 
did not exactly fit into the low-risk or high-risk groups. The management of this group of 
patients also needs to be clearly defined. 
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The commonly used variables in studies on risk factors in UGIB and their association 
with outcome are summarised in table 3. 
Table 3. Summary of frequently tested predictors of outcome in UGIB 
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Previous peptic ulcer disease 
Previous surgery 
Melaena 
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1.2 MANAGEMENT OF UPPER GASTROINTESTINAL BLEEDING 
1.2.1 The role Endoscopy and Endoscopy Therapy 
Endoscopy has provided physicians with a view of the gastrointestinal tract 
unprecedented in the history of medicine. However, in the initial phase, the precise role 
of endoscopy had been argued (Petrini Jr 1988). This was because the anticipated 
benefits of early diagnosis offered by endoscopy had little effect on overall management 
such as, reduced transfusion requirements, more rational use of surgery, decreased 
hospital stay and the overall mortality had remained unchanged (Graham 1980, Eastwood 
1981 ). But if diagnostic and therapeutic techniques were not improving, mortality rate 
would have worsened with the increasing age of patients presenting with upper 
gastrointestinal bleeding, as mortality is highest in the elderly (Whigham 1991 ). 
Optimal management of a patient presenting with upper gastrointestinal bleeding includes 
endoscopy (Terdiman 1998). Endoscopic management of upper gastrointestinal bleeding 
has been expanded from a purely diagnostic role to a therapeutic role (Steffes 1992). 
Meta-analyses based on systematic literature reviews ofrandomised controlled trials have 
demonstrated that endoscopic therapy in peptic ulcer disease is effective in reducing the 
rate of re bleeding, the need for surgery and the mortality rate (Henry 1988, Cook 1992). 
Not only is endoscopy useful in improving outcome in UGIB but it is the most sensitive 
and specific diagnostic procedure for determining the cause and site of bleeding. It 
provides information regarding (a) location and identity of the bleeding source, (b) 
bleeding rate and (c) whether stigmata ofrecent haemorrhage (SRH) (active bleeding at 
endoscopy, an old or fresh clot, a visible vessel or an ooze) are present (O 'Connor 1992). 
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Despite its sensitivity and specificity, repeat endoscopy may be required in 8 to 10% in 
whom the bleeding source is undetermined (O'Connor 1992). 
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Peptic ulcer is the most common bleeding lesion accounting for 50% of all bleeding from 
upper gastrointestinal tract (Silverstein 1981 ). Bleeding ceases spontaneously in 75% to 
85% of the cases (Gilbert 1981 ). Not all patients with upper gastrointestinal bleeding 
require or should be considered as candidates for endoscopic therapy. Age is a primary 
consideration since mortality appears to be higher in patients over the age of 60 years in 
whom prolonged bleeding or delay of treatment may increase the likelihood of a poor 
surgical outcome (Morris 1984). Active bleeding, fresh red clot adherent to ulcer base or 
a visible vessel indicates a tendency towards re bleed with a recurrence rate of nearly 40% 
(Griffiths 1979, Wara 1985). The probability of continued bleeding or rebleed may be as 
high as 85% for active arterial bleeding, approximately 40% for a fresh clot on an ulcer 
and 5 to 10% for a flat, pigmented spot. A clean base on an ulcer reliably indicates that 
the ulcer is not likely to bleed (O'Connor 1992) 
Endoscopic sclerotherapy is a reasonable therapeutic alternative for varices that have bled 
once, as rebleed is likely (Graham 1981 ). Arteriovenous malformations and the lesion 
associated with Osler-Weber Rendu disease (hereditary haemorrhagic telangietasia) are 
also likely to rebleed, although the bleeding is usually not life-threatening. The primary 
goal of therapy in these situations is elimination of the need for continued transfusion 
(Petrini Jr 1988). Mallory-Weiss (oesophageal) tear rarely requires therapy, since 
bleeding stops spontaneously in about 90% of cases (Sugawa 1983). 
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1.2.1.1 Specific Endoscopic Treatments 
Specific endoscopic therapeutic techniques greatly increase the utility of upper 
endoscopy in patients with gastrointestinal bleeding. These are: injection, thermal, 
combination thermal and injection treatments and mechanical haemostasis. 
• Injection treatment 
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This is the treatment of choice in many institutions. The injection commonly consists of 
dilute epinephrine (adrenaline), which causes vasoconstriction. This is injected around 
and into the bleeding point. Other materials used are ethanol or hypertonic saline and a 
combination of thrombin and fibrinogen (fibrin tissue glue). Studies have not shown 
definitive evidence as to which material is superior. Benefit has been shown in treatment 
groups compared to controls (Pascu 1989, Rutgeerts 1989, Balanzo 1990, Chung 1991 
Asaki 2000) in that need for surgery and overall mortality were reduced. 
• Thermal treatments 
Laser thermocoagulation was the first endoscopic therapy used to treat bleeding ulcers. 
This has been replaced by cheaper and more user-friendly methods. Most institutions use 
heater probe thermal haemostasis but recently argon plasma coagulator (APC) has been 
instituted (Palmer 2000). APC is a no-touch treatment with relatively superficial damage 
and therefore low risk of complications such as ulceration, induction of bleeding and 
perforation associated with other modes of therapy (O'Connor 1992). 
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• Combination injection and thermal treatment 
Studies have failed to demonstrate significant overall benefit for combination therapy. 
Chung et al. (1991) compared combination of epinephrine and heater probe coagulation 
versus epinephrine alone. They demonstrated slight benefit in a subgroup of patients who 
had most severe active haemorrhage, as they tended to have fewer rebleeding episodes 
and required surgical intervention less often when treated by combination method. 
Though this may demonstrate some clinical benefit, supportive evidence is currently 
lacking to translate this into standard clinical practice (Palmer 2000). 
• Mechanical haemostasis 
A range of physical methods has been used to arrest ulcer bleeding. The most promising 
of which is the use of haemoclips. Studies comparing injection treatment with haemoclip 
or a combination of the two have demonstrated a slightly better outcome in the haemoclip 
or combination therapy. In a study by Chung et al. (1999) of 124 patients with actively 
bleeding or visible vessel who were randomly allocated to the treatments, rebleeding rate 
was lowest (2.4%) in those receiving haemoclip alone, 9.5% in those receiving 
combination treatment (haemoclip and hypertonic saline-epinephrine injection) and 
14.6% in patients treated by injection alone. Total haemostasis was achieved in 95% of 
patients receiving haemoclip or combination treatment and 85% of those treated with 
injection alone. Villanueva et al. (1996) similarly randomised 79 patients to epinephrine 
injection or combination of epinephrine injection and haemoclip. The rebleeding rate 
was lower in the combination group, hospital stay was shorter and transfusion 
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requirements lower in the haemoclip group, but no difference in mortality and 
requirement of surgery was noted. 
1.2.1.2 Failure of Endoscopic therapy 
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Endoscopy therapy is unsuccessful in 15-20% of patients (Palmer 2000). Patients at 
highest risk of failing endoscopy therapy are those who present with anaemia, shock and 
active arterial bleeding from a posterior duodenal ulcer (Villanueva 1993). Lau et al. 
(1999) have studied outcome in patients who rebleed following initial endoscopic 
haemostasis. They compared outcome in patients who were randomised either to repeat 
endoscopic therapy ( 48 patients) or surgery ( 44 patients) over a 40 month period. In 73 % 
of patients haemostasis was achieved after repeat endoscopy but the remaining 27% had 
surgery (23% for failure of treatment and 4% for perforation resulting from 
thermocoagulation). The complication rate was 36% in the surgical group and 14% in 
the endoscopy group. The mortality rate was 18% in the surgical group and 10% in the 
endoscopy group. The length of hospital stay and blood transfusion requirements was 
similar in the two groups. On multivariate analysis, hypotension at randomisation (p = 
0.01) and ulcer size of at least 2 cm (p = 0.03) were independent predictors of failure of 
endoscopy therapy. The conclusion from this study was that when patients rebleed after 
initial haemostasis has been achieved, it is worthwhile to re-treat using endoscopic 
methods. 
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1.2.2 Role of Medical Therapy 
• Inhibitors of Acid Secretion 
Studies have so far not demonstrated any practical and beneficial medical therapy in the 
management of acute upper gastrointestinal bleeding. The primary role of medical 
therapy is in the healing of peptic ulcers. 
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The first pharmacological treatment which promoted the healing of peptic ulcers were the 
histamine2 (H2) receptor antagonists e.g. cimetidine and ranitidine which inhibit gastric 
acid secretion. Later, proton pump inhibitors (PPI), e.g. omeprazole and lansoprazole 
were introduced. These are more potent inhibitors of acid secretion than the H2-
antagonists. 
There is conflicting evidence about the role of these drugs in the control of upper 
gastrointestinal bleeding (Jenkins 1999). Daneshmend (1992) in a placebo-controlled 
trial of omeprazole failed to demonstrate any difference between treatments with respect 
to recurrent bleeding, transfusion requirement, need for surgery and mortality. The 
problem with this study is that they included all patients with UGI bleeding, 80% of 
whom would have stopped bleeding spontaneously as a result of intrinsic haemostatic 
mechanisms (Steffes 1992), diluting any difference in effect. However, omeprazole has 
been found to improve outcome and reduce need for invasive therapy in placebo-
controlled trials that only included patients with prognostic signs indicative of re bleeding 
(Khuroo 1997, Hasselgreen 1997, Schaffalitzky de Muckadell 1997). 
Some studies have compared omeprazole versus H2-receptor antagonists in the setting of 
acute UGI bleeding. Lin et al. (1996) randomised 31 patients to omeprazole and 32 
patients to cimetidine intravenously for 3 days. Both groups received endoscopic therapy 
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for actively bleeding ulcers and non-bleeding visible vessels. This study reported a 
significantly different rebleeding rate of 3 .2% versus 28.1 % in favour of omeprazole. 
Lanas et al. (1995) randomised 51 patients with acute UGI bleeding to intravenous 
omeprazole and ranitidine. Baseline characteristics were matched in both groups; none 
received endoscopic therapy. Re-bleeding rate and surgery requirements were 
significantly reduced in favour of omeprazole. Gastric juice alkalisation has been shown 
to reduce clot lysis (Patchett 1995). This could explain the beneficial effect of acid 
inhibition in the setting of acute gastrointestinal bleeding. In contrast to the findings of 
Lanas et al. ( 1995), Villanueva (1995) noted no difference in the rate ofrebleed, 
emergency surgery, need for transfusion and length of hospital stay in two groups of 
patients randomised to receive intravenous omeprazole ( 45) or intravenous ranitidine 
( 41 ). Lau et al. (2000) in a double blind trial, randomised 240 patients with actively 
bleeding ulcers or ulcers with nonbleeding visible vessel to high dose intravenous 
omeprazole or placebo (120 in each group) for 72 hours followed by oral omeprazole for 
8 weeks. These patients were all treated with an epinephrine injection followed by 
thermocoagulation prior to randomisation. The primary end point was recurrent bleeding 
within 30 days after endoscopy. Bleeding recurred within 30 days in 6. 7% in the 
omeprazole group, and 22.5% in the placebo group. 
The use of standard or high dose H2-receptor antagonists or omeprazole to prevent 
recurrence of bleeding is currently controversial as there has been no consistently 
demonstrable benefit in patients with acute gastrointestinal bleeding (Peterson and Cook 
1998). A pooled analysis of different studies has been difficult because of the 
heterogeneity of the patients enrolled to these studies, the variable endoscopic stigmata of 
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recent haemorrhage (SRH) and different baseline risks of re bleeding, different dosages 
and duration of trial medication and different cointerventions (Peterson and Cook 1998). 
Treatment should however be initiated to promote ulcer healing (Laine 1994). 
There is nothing to choose between the currently available PPis ( omeprazole, 
lansoprazole and pantoprazole ). The speed of healing is proportional to the intensity of 
acid suppression and the duration for which gastric pH is kept above 3. H2-receptor 
antagonists maintain the pH above 3 for 8-12 hours and PPis for 15-17 hours (Tytgat 
1998). 
• Somatostatin and Octreotide 
Somatostatin is a hormone and octreotide is its synthetic analogue. 
Somatostatin exerts a number of effects on the gastrointestinal tract that may be 
beneficial in the control of non-variceal UGI haemorrhage. 
a) It inhibits basal and stimulated gastric acid and pepsin secretion (Konturek 1985, 
Mogard 1985), thereby promoting platelet aggregation and facilitating the 
formation of occlusive thrombus. 
b) It reduces gastric mucosa! blood flow (Li 1996) and gastric perfusion (Panes 
1994), thus may be beneficial in decreasing the risk ofrebleeding. 
c) It stimulates mucous protection, which forms the main protective barrier between 
the gastric mucosa and digestive actions of acid and pepsin. This may be 
beneficial in both preventing early recurrent bleeding from ulcers and in 
promoting ulcer healing (Jenkins 1999). 
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Octreotide inhibits basal and stimulated gastric acid secretion (Whitehouse 1986, Olsen 
1987) but it is not yet known whether it has an effect on gastric blood flow, pepsin 
secretion or mucous production (Jenkins 1999). The inhibitory effects on gastric acid 
secretion of octreotide are short lived being lost after 7 days of continuous, low dose, 
subcutaneous administration, owing to down regulation or internalisation of somatostatin 
receptors involved in inhibiting acid secretion (Londong 1989). 
• Comparative Studies of Somatostatin and Octreotide in UGI Bleeding 
Trials comparing the effects of somatostatin versus H2-receptor antagonists, omeprazole, 
or placebo (Coraggio 1989, Tulassay 1989) suggest that somatostatin significantly 
reduced the rate of rebleeding compared with ranitidine and omeprazole. These studies 
only included patients with stigmata prognostic of recurrent bleeding. Preliminary results 
of a randomised controlled trial have a similar findings with rate of rebleeding of 6% in 
those treated with somatostatin and 18% in those treated with either ranitidine or 
omeprazole following endotherapy (Jenkins 1999). 
Randomised trials that included low risk patients have failed to demonstrate any 
beneficial effects of somatostatin (Somerville 1985, Panes 1994, Basso 1986). Inclusion 
of such low risk patients would probably have diluted the effects of somatostatin as in 
80% bleeding will cease spontaneously (Steffes 1992). 
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Imperiale and Birgisson (1997) conducted a meta-analysis based on systemic English-
language literature review of randomised clinical trials comparing somatostatin or 
octreotide with H2 blockers or placebo in patients with clinical or endoscopic diagnosis of 
acute nonvariceal upper gastrointestinal haemorrhage. There was a reduced rate of re-
bleeding or continued bleeding (RR 0.53 ; 95% CI, 0.43-0.63) in favour of somatostatin. 
The efficacy of somatostatin was more in peptic ulcer bleeding (RR 0.48 ; CI, 0.39-0.59) 
than in non-peptic ulcer haemorrhage (RR 0.62; CI, 0.39-1.002). The overall result 
suggested a decreased need for surgery in the somatostatin group, but a subgroup analysis 
of investigator-blinded trials revealed a more modest effect that was not statistically 
significant (RR 0.94; CI, 0.87-1.001). 
Octreotide has not been well studied. Small randomised controlled trials with this drug 
suggest that its effect on control of bleeding is lower than that of somatostatin (Jenkins 
1999). 
On the basis of available data, it would seem that somatostatin may be of value in the 
treatment of acute UGI bleeding. Because of conflicting findings from various studies its 
use has not gained popularity and further studies are required (Jenkins 1999). Wider use 
of naturally occurring somatostatin may be further curtailed by its high cost (Shields 
1992). The analogue octreotide is much cheaper but not as effective. 
• Eradication of H. pylori 
A number of studies have demonstrated that successful eradication of H pylori in the 
long term reduces recurrent ulcer bleeding and subsequent complications (Graham 1993, 
Rokkas 1995, Santander 1996, Labenz 1994 Jaspersen 1995). Tygat et al. (1993) 
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reviewed seventeen trials in which patients with or without H pylori were compared. The 
follow-up period varied from 6 to 48 months after healing. The relapse rate was 71 % 
(range 20-100%) in patients with persistent infection and 0% (0-22%) in those in whom 
H pylori had been eradicated. It is suggested that only therapies that achieve over 90% 
cure rate per protocol and over 80% per intention to treat should be employed (Hunt 
1997, Maastricht Consensus Report 1997). The commonly used regimens consist of PPI-
Clarithromycin-Amoxycillin or PPI-Clarithromycin-Metronidazole. These have an 
efficacy range of 85-95% (Tytgat 1998). The regimen used will depend on the local 
prevalence rates of microbial resistance. 
Studies have shown that PPis are superior to H2-receptor antagonists or other 
pharmacological modalities in healing and maintenance of duodenal ulcers with known 
H pylori status (Hunt 1997, Howden 1997). 
1.2.3 Role of Surgery in the bleeding patient 
Surgery has had a role in the following situations: (1) non-response to medical therapy; 
(2) pyloric stenosis or hourglass contracture of the stomach from scarring; (3) suspicion 
of malignancy; ( 4) complications, such as haemorrhage and perforation. Except for the 
last indication, improvement in medical therapy has not changed the indications for 
surgical therapy in upper gastrointestinal bleeding (Jamieson 2000). ). Other reports 
have suggested that emergency surgery is on the increase because of a decrease in 
elective surgery and an increase in the incidence of NSAID-associated complications 
(Bliss 1991 ). 
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• Emergency surgery in Haemorrhage 
The advent of endoscopic therapies such as thermal therapy and injection sclerotherapy 
has greatly diminished the need for emergency surgery in bleeding peptic ulcer. 
Eradication therapy for H pylori, where it is affordable, has changed the natural history of 
peptic ulcer disease and diminished the need for surgery (Jamieson 2000). 
In the past emergency surgery would have been indicated in patients presenting with 
shock and acute anaemia; coagulopathy; other significant comorbidity and visible vessel 
or active bleeding at endoscopy (Meilahn and Ritchie 1994). Endoscopic therapy 
controls bleeding in 80% to 90% of these patients. For those where bleeding recurs or is 
not controlled, surgery is indicated (Meilahn and Ritchie 1994). Evaluation of operative 
treatment in peptic ulcer bleeding has been difficult because randomised controlled trials, 
which are the preferred scientific standards for investigating treatments are rare in this 
field (Ohmann 2000). In many trials involving medical or endoscopic therapy, surgery is 
considered as an outcome criterion rather than a treatment option (Ohmann 2000). 
Gralnek et al. (1997) in their prospective, randomised-controlled study confirmed the 
widespread belief that endoscopic forms of therapy are superior when compared to 
traditional medical/surgical therapies. Lau et al. (1999) confirmed the superiority of 
endoscopic therapy in patients with recurrent bleeding after endoscopic haemostasis. 
They randomised patients to repeat endoscopy and surgery. The surgical group had more 
complications than the group that had the repeat endoscopy group (Lau 1999). 
Surgical procedures vary from local (under-running the vessel or ulcer excision) to 
conventional (partial gastrectomy). From the available evidence, there is no difference 
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between local and radical surgery concerning mortality, although the rebleeding rate may 
be higher in the local group (Ohmann 2000). 
1.3 How should patients with Upper Gastrointestinal Bleeding be managed? 
Profile of international accepted practices: 
Important clinical questions in the management of UGIB include: 
• Should a patient be admitted to hospital? 
• How soon should endoscopy be performed? 
• Who should take responsibility (surgeons or physicians)? 
Experts in this field emphasise a team approach to the management of patients with UGIB 
where surgeons and physicians have jointly agreed policy guidelines for management of 
such patients (Sanderson 1990, Clements 1991 ). Patients should preferably be admitted to 
medical wards or specialised gastrointestinal (GI) units with close medical-surgical liaison 
and managed according to strict protocols for resuscitation, transfusion and surgery (Mueller 
1994). 
In some centres the decision as to whether to manage a particular patient as an in- or 
outpatient is made after clinical and endoscopic evaluation. In such situations there are 
guidelines encompassing absolute and less clearcut recommendations for discharge 
(Longstreth 1995). 
On the whole, accepted practice is that endoscopies are done on the next endoscopy list 
usually within 24 hours unless the case is deemed to be an "emergency" (i.e. 
experiencing life threatening UGIB) (Report of Joint Working Group 1992). 
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Ideally patients presenting with upper gastrointestinal bleeding should have the severity 
of the bleeding assessed. If the patient presents with haemoglobin < 10 g/dl, shock 
(systolic blood pressure < 100 mmHg) or has other risk factors (age> 60 years, 
comorbidity) the bleeding should be regarded as serious. Such patients should have 
adequate resuscitation with blood and be admitted where they can be adequately 
observed for re bleeding. If these patients re bleed or have continued bleeding, 
emergency endoscopy should be arranged or endoscopy should be carried out on the 
next available list. The previously fit patient can be observed in a general medical ward 
and undergo endoscopy on the next available list to document the source of bleeding. 
A protocol of patient management has been derived (Figure 1 ). 
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Adapted from report of Joint working group 1992 and Ohmann et al. 2000 
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1.4 CURRENT PRACTICE AT GROOTE SCHUUR HOSPITAL (GSH): 
• Admission policy 
All patients with upper gastrointestinal bleeding present to the Emergency Unit. Those 
with obvious melaena or haematemesis are admitted to the emergency medical admission 
ward for further management. Patients with known oesophageal varices (which is often 
the most rapid type ofUGIB and known not to benefit from medical therapy) (Elta 1991) 
and those presenting in shock are referred to surgeons to expedite endoscopic and 
surgical intervention if necessary. 
Patients with less clear history of UGIB who are faecal occult blood negative and 
haemodynamically stable are discharged on antacids and referred for routine outpatient 
endoscopy. 
Patients over the age of 60 years with any history of gastrointestinal tract (GIT) bleeding 
are all admitted for endoscopy. 
• Endoscopy policy 
All patients who are admitted have endoscopy on the next day's routine endoscopy list. 
Over the weekends (when such services are not available) endoscopy is usually 
performed on the first weekday slate. Emergency endoscopy services are always 
available. 
There are currently 4 different waiting lists for upper gastrointestinal endoscopy: 





Urgent routine (next morning); 
Delayed urgent routine i.e. patient presenting Friday midday to Monday 
morning all have endoscopy on Monday; 
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4. Elective (out patient list usually entailing a waiting list of up to 2 months). 
For patients from G.F. Jooste and Conradie Hospitals, which are regional hospitals in the 
drainage area of GSH, endoscopy is available once a week at GSH, unless the bleeding 
does not settle in which case patients are promptly transferred to GSH and endoscopy 
performed as indicated above. 
• Resuscitation practice 
Physicians operating the endoscopy service require that all patients should have been 
adequately resuscitated, with stable haemodynamic parameters and a haemoglobin of at 
least 10 g/dl prior to endoscopy. In the case of life threatening bleeding resuscitation is 
performed during endoscopy, usually in an operating theatre. 
Endoscopy typically reveals one of the following common situations: 
• Patient with an actively bleeding ulcer - the ulcer is injected with submucosal 
adrenaline ( 1: 10 000 - 20 000) to bring about haemostasis. 
• Patient with features suggesting a high risk ofrebleed (active bleeding at 
endoscopy, an old or fresh clot, a visible vessel or an ooze) is observed for a 
further 92 hours in hospital regardless of endotherapy as re-bleeding has been 
commonly found to occur within three days (Laine 1994 ). 
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• Patient with gastric ulcers - routinely have biopsies taken from the wall of the 
ulcer to exclude gastric carcinoma unless they are actively bleeding in which case 
they are rescoped once bleeding has settled. All patients with gastric ulcers are 
rescoped after one month of medical ulcer healing therapy after which time the 
ulcer is expected to have healed. If the ulcer hasn' t healed repeat biopsies are 
taken, compliance with therapy is reviewed and medical therapy is given for a 
prolonged period depending on biopsy results. 
• Patient with bleeding varices - the varices are injected with sclerosant 
(Ethanolamine oleate) or banded to secure haemostasis. 
All patients with non-bleeding gastric and duodenal ulcers are discharged soon after 
endoscopy on ulcer healing therapy that commonly consists of a proton pump inhibitor 
with or without antibacterial therapy for eradication of H pylori . Indications for the 
latter therapy are a positive urease test for H Pylori (Laine 1994 ). 
• Criteria for Emergency scope: 
The general practice in the hospital is that following admission the patients are 





Patient has known oesophageal varices; 
Patients presents evidence of a rebleed (hypovolaemia, fresh 
haematemesis or drop in haemoglobin of>3g when there is no evidence of 
bleeding); 
Patient continues to bleed (haemoglobin and blood pressure and pulse not 
stabilising despite resuscitative measures) . 
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These patients are generally referred to surgeons, as they would possibly require surgical 
intervention. 
Patients found to have gastric, oesophageal or other gastrointestinal malignancy are also 
referred to surgeons. 
1.5 Pressures on local endoscopy services 
Groote Schuur Hospital (location for the current study) has experienced a significant staff 
cutback over the past 5 years. Few of our regional hospitals and none of our primary 
health care facilities have endoscopy facilities and endoscopic expertise is similarly 
limited. Given the pressures on the limited endoscopy services, there is a need for 
guidelines for the referral of patients to centres with these facilities. Diagnostic 
endoscopy without a therapeutic procedure does not alter mortality (Dronfield 1982, 
Erickson 1986), though in most cases it provides information on the source of bleeding. 
Our community would benefit more if these services were aimed at patients to whom it 
would be most beneficial, that is in whom it would alter management decisions. If only 
the deserving patients were to undergo endoscopy, the waiting list for non-urgent 
endoscopies which is currently stands at 2 months would be shortened as the need for 
emergency endoscopy would diminish, leaving time for elective endoscopy. It would 
hence be beneficial to be able to predict patients who would do well regardless of 
whether they underwent endoscopic examination or not. 
There is a possibility that the number of potential referrals of UGIB cases will increase as 
the primary health care services improve, a rational review of criteria for referral 
appeared timely. There would be need to triage patients into: 
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i). those who must have endoscopy urgently and 
ii). those who could be safely referred for elective endoscopy. 
1.6 Study Rationale 
Given the scarcity of both endoscopy resources and of information for the triage of 
patients who would recover uneventfully following UGIB without urgent endoscopy, this 
study set out to answer the question: 
1.6.1 QUESTION: 
Is it possible to identify clinical criteria that will predict patients with UGIB in 
whom endoscopy could be safely deferred? 
1.6.2 PURPOSE: 
To identify patients at low risk for an adverse outcome following an upper 
gastrointestinal bleed. 
1.6 .. 3 AIM: 
• To identify patients who would not require in-patient hospital care following 
upper gastrointestinal bleeding (UGIB) by: 
• Identifying the key clinical variables prior to endoscopy that predict uneventful 
recovery. 
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1.6.4 OBJECTIVES: 
• To identify clinical criteria that predict uneventful recovery. 
• To determine the accuracy of individual symptoms and signs or combinations of 
symptoms or signs at the time of presentation in predicting uneventful recovery. 
CHAPTER 2: METHODS 
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2.1 Study population and Methods 
· 2.1.1 Study Design: 
The design was a prospective, descriptive, cross sectional study with an analytical 
component. 
2.1.2 Study population 
Inclusion criteria 
41 
The study population included consecutive patients over the age of 12 years 
presenting to the Emergency unit of GSH with haematemesis and/or melaena between 
October 1997 to August 1998. 
Exclusion criteria 
Patients were excluded: 
• If their initial presentation was to another hospital that instituted resuscitative 
measures; 
• If they were known to have oesophageal varices or upper gastrointestinal 
malignancy; 
• If they presented with anaemia without a clear history of UGIB; 
• If they developed UGIB during the course of hospitalisation for another problem. 
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2.1.3 Study setting 
Groote Schuur Hospital (GSH) which is a tertiary referral teaching hospital with 1470 
beds. It is affiliated to the University of Cape Town. The hospital provides both 
secondary and tertiary care to a racially and socio-economically mixed patient 
population. 
All patients admitted to GSH with upper gastrointestinal bleeding (UGIB) initially 
present to the Emergency Unit. 
2.1.4 Independent variables (potential predictors) 
The clinical predictors of interest were presyncope or syncope, use of non-steroidal 
anti-inflammatory drugs (NSAID), salicylates, or warfarin, history of alcohol 
ingestion (see definitions), history of previous peptic ulcer disease, haemoglobin 
concentration, pulse, systolic blood pressure, postural hypotension, age and 
comorbidity. 
2.1.5 Outcome ( dependent) variable considered: 
Good outcome 
I. Non-performance of: -
a. an endoscopic procedure (endotherapy) to control bleeding, 
or 
b. a therapeutic surgical procedure, 
or 
c. a blood or blood product transfusion, 
and 
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2. Alive on discharge and no death related to UGIB within the month of initial 
presentation. 
ii Poor outcome, i.e. any patient who had anyone of the above events. 
Death in hospital or in the first month of presentation. The deaths were divided into: 
i) those that were directly related to the gastrointestinal bleeding and ii) those that 
were not directly related to gastrointestinal bleeding. 
2.1.6 Management criteria 
Criteria for admission changed in that all patients who presented with UGIB during 
the period of the study were admitted to the emergency admission ward regardless of 
severity of bleed. Timing of endoscopy remained as is currently practiced (see under 
current practice at Groote Schuur Hospital). 
Referral to surgeons was maintained as is currently practiced. 
2.1. 7 Data collection 
Data was collected on a structured clerking sheet (see appendix A), which was 
designed for the study. On admission every patient had this clerking sheet filled in by 
the casualty officer who collated the patient's history, findings and management prior 
to endoscopy. 
No formal training was given to the casualty officers in the use of the clerking sheet 
but they were informed of the study and use of the study questionnaire as a clerking 
sheet for all patients presenting with UGIB. A written note was left in the casualty 
unit informing the casualty officers of the ongoing study. 
A pilot study was conducted using the first ten patients. The casualty officers were 
asked for their input on any ambiguities. Except for the layout, no major changes 
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were made to the questionnaire. 
History 
Information collected from history included: -
• Demographic data (name, age gender, race, hospital number, home address, 
telephone number (home or work where applicable), date of admission and 
date of discharge or death) ; 
• History of the current bleed, which included duration of the current bleed (in 
hours) and any other recent episode of bleeding (in days); 
• Whether the bleed was a haematemesis or melaena or both; 
• Pre-syncope or syncope; 
• Medication use, particularly use of salicylate, non-steroidal anti-inflammatory 
drugs and anticoagulants at the time of the bleed; 
• Social habits (smoking and alcohol use) at the time of the bleed; 
• History of previous peptic ulcer; 
• History of other underlying disease (obtained from the patient and hospital notes 
where these were available). 
Physical examination 
Physical examination at the time of admission included: -
• Haemoglobin (gm/dl) by fingerprick method, using a BMS Haemoglobinometer 
(Linegar 1991 ); 
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• Blood pressure (in millimetres of mercury) measured by the admitting doctor with 
a mercury sphygmomanometer. This was done in a supine, sitting and where 
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possible also in a standing position; 
• Pulse measured in beats/min using a watch with a second hand counted over 
one minute. 
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Following admission, nursing staff checked blood pressure and pulse every 6 hours or 
half-hourly if on blood transfusion. Haemoglobin was checked every I 2 hours. 
Other examination included: 
• Palpation for lymphadenopathy including a Virchow's (VT) node which is a 
palpable lymph node in the supraclavicular fossa as a sign of metastatic gastric 
carcmoma; 
• Abdominal examination for tenderness, abdominal mass, visceromegaly, rectal 
examination, inspection of vomit/stool (noting colour) and testing for occult blood 
in stools with Haemoccult test (Rockey 1999); 
• Examination of cardiovascular, central nervous, musculoskeletal, renal and 
respiratory systems for evidence of other underlying disease. 
Endoscopic findings 
At endoscopy the endoscopist recorded the following: 
• Identification of the source of bleed; 
• Stigmata ofrecent bleeding. These were any of the following: - a bleeding visible 
vessel, a visible vessel, an adherent clot, ooze or a fresh clot; 
• Endoscopic diagnosis, that is, oesophageal varices, a Mallory-Weiss tear, 
oesophagitis, gastritis, duodenitis, peptic ulcer, neoplastic disease, any other 
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specific pathology or no pathology at all found; 
• Any specific therapeutic procedure done during endoscopy, for example 
sclerotherapy. 
At endoscopy biopsy samples were obtained where judged clinically indicated, to 
identify the presence or absence of Helicobacter pylori by rapid urease test and 
histology (Isenberg et al. 1991 ), or to determine whether the ulcer was benign or 
malignant. 
2.1.8 Management based on endoscopy as advised by the endoscopists 
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At endoscopy the endoscopist filled into the clerking sheet the endoscopic findings , 
procedures and recommendations on further management of the patient (see appendix 
A). The recommendation ranged from: 
• Medical therapy in the form of one of the following : antacids, sucralfate, 
histamine2-antagonists, proton pump inhibitors, with or without antibiotic therapy 
for Helicobacter pylori; 
• Referral for "surgical" management either to expedite endoscopy or for the surgical 
control of the bleeding or for definitive surgery for a malignant ulcer; 
• Prolonged hospital stay because of signs seen at endoscopy that indicated an 
increased likelihood of recurrent bleeding; 
• No therapy recommended, but advice on further investigation (e.g. to investigate 
the lower gastrointestinal tract). 
The principal investigator checked every admission before discharge to record the 
outcome in each patient and ensure that study pro forma had been completed. 
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2.1.9 Status at one-month follow-up 
Patients were followed up within a month of discharge from hospital by the 
fieldworker with extensive previous experience in fieldwork. She was trained by the 
principal investigator on use of the follow-up questionnaire (see appendix B) and the 
importance of the patients being reviewed within a month following discharge. 
The follow-up questionnaire had the same study number as the main questionnaire for 
each patient. The questions in the questionnaire related to how the patient rated their 
health at the time of the follow-up, whether they had been booked for a repeat 
endoscopy, whether the symptoms had resolved and whether they had a recurrent 
bleed. If they had died, the principal investigator made a judgement as to whether 
death was related or unrelated to the bleed. This was determined by interviewing 
relatives and reviewing hospital notes where death occurred in hospital. 
Before discharge from the hospital all patients consented to the telephonic contact or 
home visit that would be made by the fieldworker to check on their progress. The 
follow up was done telephonically in the majority of cases. Where a telephone was 
unavailable, the patient was visited at his/her home address. 
Patients that could not be contacted after five telephone calls or three home visits were 
classified as "lost to follow-up". For every patient lost to follow-up, the field worker 
made a comment as to why contact was not made. 
2.2 Sample size calculations 
There were 11 clinical predictors (variables) of interest for this study. These were: 
age, use ofNSAID and/or salicylates, use of anticoagulation (warfarin), history of 
ingestion of alcohol, history of previous peptic ulcer disease, a history of pre-syncope 
or syncope, the presenting blood pressure, pulse and haemoglobin and comorbidity 
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status. Using general guidelines that at least 10 events are required for each 
independent variable included in a logistic regression model, a sample with 110 or 
more patients was considered adequate (Peduzzi 1996). Since comorbidity had 7 
subgroups (cardiac, renal, pulmonary, hepatic, haematology, central nervous system, 
musculoskeletal) and history of ingestion of alcohol had 2 subgroups (alcohol binge 
and alcoholism) bringing the total variables to 20, a target sample size was set at 200 
patients. 
2.3 Instruments used: validity and reliability 
• Questionnaire: 
Most of the questions were closed with space provided for comments. Old hospital 
records in those patients who previously had been seen at the hospital supplemented 
this information. 
• Measurement of Haemoglobin (gm/di) 
Due to cost constraints, laboratory haemoglobin by Coulter counter was not routinely 
done. The haemoglobin was measured using the Buffalo Medical Specialities (BMS) 
Haemoglobinometer Model 10-101 DR. This is a compact battery powered Miniature 
Photometer. It measures haemoglobin content of blood by the oxyhaemoglobin 
method. The BMS Haemoglobinometer compares the absorption of light through a 
layer of haemolysed blood ( oxyhaemoglobin) to that of a standardised glass wedge. 
If regularly calibrated this is accurate to 5% (0.6 gm/dl) of the true haemoglobin value 
over the range of 4-20 gm/dl [Manufacturer' s manual]. The validity and reliability of 
the BMS haemoglobinometer has been tested in a local study of I 00 consecutive 
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venous samples submitted to the haematology laboratory, and has been found to be 
good. The average error was between 5% and 6% (0.6 g/dl) of the laboratory 
haemoglobin value (Linegar 1991). 
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Nursing staff check haemoglobin. If the reading is low or it does not match the 
clinical context, then a doctor or another nurse is asked to recheck the colour co-
ordination. In this study some readings, especially if very low (8gm/dl or low), were 
verified with a second sample that was sent to the laboratory. This was done at the 
discretion of the attending doctor. 
• Blood pressure 
Blood pressure (systolic and diastolic) readings were measured using a mercury 
sphygmomanometer. There was no special training for the study in taking these 
measurements, as this forms part of the routine measurements done on all patients 
presenting to the emergency unit. Every member of the staff used the standard 
method of recording blood pressure as recommended by the American Heart 
Association (1967). 
A specific requirement for the study was that the admitting doctor took the initial 
measurements in a supine, sitting and standing position. This was to check for a 
postural drop in blood pressure, which, if present, would suggest volume depletion. 
Blood pressure was measured 4 hourly thereafter. In situations of continued bleeding 
the measurements were done at hourly intervals. 
Blood pressure measurements are liable to a number of errors: 
i) Inter-observer variation as they were recorded by different nursing staff on the 
ward; 
ii) Use of a wrong sized cuff e.g. an obese patient using a standard size cuff will 
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give falsely high readings; 
ii) An instrument that is not well calibrated; 
iii) Changing emotional state and position of the patient. 
• Pulse recording 
The radial pulse was counted over one minute, using a watch with a second hand. 
The blood pressure and pulse rate values used in the text were those measured at the 
time of presentation to hospital. 
• Haemoccult test (Bayer) 
This is a guaiac-based test that relies on peroxidase activity of heme in haemoglobin. 
Theoretically it should be able to detect blood in the stool from all parts of the 
gastrointestinal tract. However, in bleeding from the upper gastrointestinal tract, false 
negative results may occur as intestinal enzymes and/or bacteria degrade haemoglobin 
introduced into the upper gastrointestinal tract to porphyrin. The proportion of 
positive tests increases with increased amounts of blood loss (Rockey 1999). Feacal 
haemoglobin levels must exceed 10 mg/g (1 0 ml daily blood loss) before the 
haemoccult test is positive at least half the time. Certain fruit and vegetables such as 
turnips. cauliflower, grapes and broccoli have a perioxidaselike activity giving false 
positive reactions (Macrae 1982). 
• Endoscopy 
This is prone to inter-observer variation even when done by physicians experienced in 
endoscopy. The higher the number of such endoscopists involved the lower the inter-
observer agreement. This has been demonstrated in the following studies. 
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1. Twenty- five videotapes from endoscopic examinations of patients with 
recent non-variceal upper gastrointestinal haemorrhage were shown to 47 
expert endoscopists. The endoscopists were asked to classify every lesion 
for features of stigmata of recent haemorrhage according to Forrest' s 
classification. Forrest classified endoscopic appearance oflesions into: 
FIA, FIB, FIIA, FIIB, FIIC and FIII (see definitions). Three independent 
experts had agreed on the Forrest's classification of each lesion. Agreement 
was expressed as of kappa statistics (see definitions). Kappa statistics were 
calculated for each class of Forrest's classification. For FIA, kappa= 0.76 
and FIB, kappa= 0.61. For other lesions kappa varied from 0.44 to 0.49 
(Mondardini 1998). 
11. Gastroenterologists were shown videos of endoscopic images to investigate 
whether they would agree on the definitions of lesions within the stomach seen at 
endoscopy. There was a 100% overall agreement (kappa= 1.0) for patients not 
taking non-steroidal anti-inflammatory drugs (NSAID). For lesions in patients 
taking NSAID, the overall agreement was 52% with a kappa statistic of 0.37. 
Ulcers in patients on NSAID are often more superficial and difficult to distinguish 
from erosions (Hudson 1994). 
2.4 Statistical Methods 
Data was entered into a standard spreadsheet (Excel) and univariate, bivariate and 
multivariate descriptive statistics were derived using STATISTICA VERSION 5.1 
1998 software. Bivariate analysis for the individual predictive factors for a good 
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outcome was performed using the Chi-square test (with a Yates correction) or Fisher 
exact test. Continuous variables were compared using the two-tailed Student t-test. 
To increase clinical relevance the continuous variables were also converted into 
categorical variables by grouping them into ranges. The cut-off values were 
determined before analysis, and are those that are internationally accepted as defining 
severity of an UGIB. Associations were expressed as relative risk with 95% 
confidence intervals for bivariate analysis and odds ratios with 95% confidence 
intervals for multiple logistic regression analysis. A 5% level of significance was 
used. 
Clinical predictors that showed significant association with good outcome on bivariate 
analysis (p = 0.10 for inclusion and 0.05 for retention) were entered into multiple 
logistic regression models . A final model was selected using stepwise multiple 
logistic regression analyses. Variables with p >0.05 were excluded from the model. 
Sensitivity, specificity, positive predictive value, negative predictive value, likelihood 
ratio for a positive test and likelihood ratio for a negative test were calculated 
individually and in combination for the variables that were found to be independently 
associated with outcome. Ninety-five percent confidence intervals for sensitivity, 
specificity and likelihood ratios were calculated using standard methods (Simel 1991 ). 
2.5 ETHICAL AND LEGAL CONSIDERATION 
The study was approved by the Ethics and Research Committee of the Medical School 
of the University of Cape Town. There were no major ethical considerations as far as 
the patients were concerned as there was no major change in their management except 
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that patients with non-significant UGIB were admitted. A verbal consent for 
completion of the questionnaire and for a follow up visit or telephone call was 
obtained from each patient. 
53 
CHAPTER 3: RESULTS 
CHAPTER 3: RESULTS 
Results 
3.1 Data capture 
Over the 10 month period of the study, a total of 306 patients were admitted to the 
emergency admission ward with a diagnosis ofhaematemesis and/or melaena. Of 
these, 218 (71.24%) had their data captured on the questionnaire. A total of 200 
(91. 7%) of these patients met the inclusion criteria and were included in the final 
analysis. The reasons for the exclusion of the 18 were varied: 2 were known to have 
oesophageal varices; 2 were unfit for endoscopy ( end stage chronic obstructive 
airways disease); 3 refused endoscopy; 7 did not have haematemesis or melaena at 
presentation; 3 did not co-operate with the endoscopic procedure and 1 was a 
readmission within 4 weeks of the initial admission. 
3.2 Patient characteristics 
3.2.1 Age and gender 
The median age for the 200 patients was 57.5 years and the interquartile range 43.7-
71.4 years. The male: female ratio was 1.6: 1 with 122 (61 %) males and 78 (39%) 
females. 
3.2.2 Manifestation of haemorrhage 
• History of haematemesis and melaena 
All patients included in the study presented with either a history of haematemesis or 
melaena, or both. The proportion of patients with haematemesis, melaena, or both is 













• Faecal occult blood (FOB) test and history of haematemesis and melaena. 
One hundred and sixty nine (84.5%) of the 200 patients had a faecal occult blood test 
performed. The numbers and percentages of their FOB test status is shown in table 4. 
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A larger proportion of patients with a history of melaena had positive FOB test than 
those with history of haematemesis alone. The difference in proportions was 
significant (p < 0.001) 
Table 4: History of melaena and FOB test status 
Presentation FOB +ve FOB-ve Total *p 
Melaena 121 (94.5%) 7 (5.5%) 128 {75.7%) 
No melaena 25 (61%) 16 (39%) 41 (24.3%) <0.001 
Total 146 (86.4%) 23 (13 .6%) 169(100) 
+ve= positive ; -ve = negative; *chi square test 
3.3 Potential risk factors present on history: 
3.3.1. Previous peptic ulcer disease (PUD) 
Fifty-nine (29.5%) gave a history of previous peptic ulcer disease. One hundred and 
twenty three ( 61. 5%) gave no history of previous peptic ulcer disease, whereas 18 
(9%) did not know whether they had had previous peptic ulcer disease or not. 
3.3.2. NSAID and Salicylate intake at time of the bleed 
Thirty-eight (19%) of patients were taking non-steroidal anti-inflammatory drugs 
(NSAID) while 66 (33%) were taking salicylates. Seventeen (8.5%) admitted taking 
NSAID and salicylates concurrently. Therefore, a total of 87 (43.5%) of patients were 
taking ulcerogenic drugs at the time of presentation. Eleven (5.5%) did not know 
whether they were taking NSAID or salicylates. For analysis, these were regarded as 
not taking these drugs. 
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3.3.3. History of current anticoagulant consumption 
Twenty ( 10%) patients were taking warfarin at the time of presentation ( 1 for deep 
vein thrombosis and 19 for cardiac disease of whom 9 had atrial fibrillation and 10 
had valvular heart disease either with or without valvular surgery). The median 
international normalised ratio (INR) at presentation was 4.1 , with a range from 0. 9 to 
greater than 10, and an interquartile range of 2.5-6.4. 
3.3.4. Alcohol 
Forty-one (20.5%) gave a history of an alcohol binge prior to onset of symptoms. 
Thirty-five (17.5%) gave a history of chronic alcoholism. 
3.3.5. Comorbid diseases 
• Cardiac disease 
A history of cardiovascular disease was present in 71 (35.5%). The disease 
distribution was as follows: hypertension 22 (30.9%), ischaemic heart disease 
37 (52.1 %), arrythmias 14 (19.7%), peripheral vascular disease 1 (1.4%) and 
pulmonary embolism 1 (1.4%). The commonest arrhythmia was atrial fibrillation 
occurring in 9 (64%) of the 14 patients with arrythmias. Of those with cardiac 
disease, 17 (23.9%) were in congestive cardiac failure at the time of presentation. 
Note that some patients had a combination of these cardiac diseases. 
• Pulmonary disease 
A history of pulmonary disease was present in 29 (14.5%). This included chronic 
obstructive airways disease (COAD) 21 (72.4%), asthma 4 (13.8%), bronchiectasis 3 
(10.3%) and chronic fibrosing alveolitis 1 (3.4%). 
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• Renal disease 
A history of renal disease was present in 14 (7%). Of these 9 (64.3%) had chronic 
renal failure. 
• Hepatic disease 
Ten (5%) patients had hepatic disease. Of these 5 (50%) had liver cirrhosis (4 of the 5 
gave history of excessive alcohol intake), 1 (10%) had cancer of the breast with 
metastasis to the liver and 4 had hepatomegaly of unknown etiology. None had a past 
history of oesophageal varices. 
• Haematological disease 
Three (1 .5%) had a history of haematological disease. All had lymphoma. 
• Neurological disease 
Twelve (6%) patients had neurological disease. These included previous stroke 5 
( 42%) of whom 2 were taking salicylates, encephalopathy due to alcoholic liver 
disease 5 (42%), peripheral neuropathy 1 (8%) and dementia 1 (8%). 
• Musculoskeletal disease (MSS) 
Twenty-six (13%) patients had a history of musculoskeletal disease. Twenty-one 
(81 % ) of the 26 were due to arthritis, either rheumatoid or osteoarthritis. One ( 4%) 
had gout arthritis and 4 ( 15%) had undiagnosed musculoskeletal aches and pains. 
Eighteen ( 69%) of the 26 patients were taking NSAIDs. 
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3.3.6. Pre-syncope and syncope 
One hundred and six (53%) of the patients had symptoms of pre-syncope or syncope. 
3.4 Haemodynamic Assessment 
• Blood pressure 
At the time of admission, 21 (10.5%) patients had a systolic blood pressure (SBP) of 
less than 100 mm Hg. The median (SBP) was 130 mm Hg with a range of 70 to 220 
mm Hg. The interquartile range was 110 to 150 mm Hg. 
• Pulse 
Eighty ( 40%) had a pulse rate of greater than 100 beats per minute. The median pulse 
rate (interquartile range) was 97 (80-104) beats per minute. 
• Postural blood Pressure 
Supine and sitting blood pressure were recorded in 136 (68%) of the patients. Of 
these, 25 (12.5%) had a postural drop in blood pressure of greater than 20 mm Hg. 
• Patients with shock at presentation 
Eleven (5.5%) patients met the study criteria for shock of a systolic blood pressure of 
less than 100 mm Hg and a pulse rate of greater than 100 beats per minute. An 
additional 10 (5%) had systolic blood pressure less 100 mm Hg but a pulse rate ofless 
than I 00 beats per minute. In total 21 (10.5%) had blood pressure less than 100 mm 
Hg at presentation. 
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• Haemoglobin 
Ninety-two ( 46%) had a haemoglobin concentration of less than 10 grams per decilitre 
(gm/dl). The median (interquartile range) was 10 (7.5-12.8) gm/dl. The range was 3 -
18 gm/dl. 
3.5 Transfusion requirements 
One hundred and two (51 %) of the 200 patients required blood transfusion. The 
minimum number of units transfused was 1 unit and the maximum was 10 units. The 
mean and median were both 3 units with an inter-quartile range of 2-4. Thirty-nine 
(19 .5%) were transfused 4 units of blood or more. See figure 3. Six patients received 
transfusion of fresh frozen plasma to control bleeding that was associated with a 
raised INR, the result of an excessive anticoagulant effect. 
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Figure 3: Transfusion requirements 
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3.6 Endoscopic diagnoses 
The largest group had peptic ulcer disease. The second largest gr ,:mp had gastritis, 
which included erosive gastritis. There were a substantial number of patients where 
the cause for the bleed was unknown. 
• Peptic ulcer 
Of the 95 ( 4 7 .5%) patients who had peptic ulcer disease diagnosed on endoscopy, the 
majority were gastric ulcers 60 (63%), 32 (34%) had duodenal ulcers, 2 (2%) had both 
gastric and duodenal ulcers and 1 (I%) had a stomal ulcer. Other causes of U GIB are 
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The miscellaneous group consisted of 2 patients with telangiectasia, 2 with gastric vascular 
malformation, 2 with duodenal polyps, 2 with Dieulafoy lesion and I with oesophageal candidiasis 
3.7 Relation between presenting factors and outcome 
The study outcome criterion was good outcome (i.e. no blood transfusion or 
endoscopic therapy or surgery, and alive one month after presentation). Eighty (40%) 
patients of the 200 had a good outcome. 
One hundred and two (51 %) were transfused. Thirty-five (17.5%) patients had 
endoscopic therapy. Eight (4%) underwent surgery. Of these 4 (50%) had surgery for 
malignant ulcer and 4 (50%) for benign peptic ulcer disease. 
There were 13 (6.5%) deaths. Of these, 8 (61.5%) deaths were related to 
gastrointestinal haemorrhage but 7 (87.5%) had other underlying comorbidity. Five 
(3 8.5%) deaths of the 13 were unrelated to UGIB, they were due to underlying 
comorbidity (2 had cardiac and chronic renal failure, 1 had chronic renal failure, 1 had 
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metastatic breast cancer and 1 had pneumonia). One patient died from gastrointestinal 
bleeding without associated comorbidity. 
3.7.1 Bivariate analysis 
3.7.1.1. Previous peptic ulcer disease and outcome 
Previous history of peptic ulcer disease was not associated with outcome. A relative 
risk (RR) of 0.90 was indicative of a 10% reduction in the likelihood of a good 
outcome, but the 95% confidence interval (Cl) did not exclude 38% reduction or 32% 
increase in likelihood of a good outcome in patients with previous peptic ulcer 
disease. See table 6. 
Table 6: History of previous peptic ulcer disease and outcome 
Outcome 
Good Poor Total RR 95% CI of RR P* 
Prev.PUD +ve 23 36 59 0.90 0.62-1.32 0.59 
Prev. PUD -ve 53 70 123 
Total 76 106 182 
*Chi square test; Prev. PUD +ve = Previous peptic ulcer disease present; Prev. PUD -ve = Previous 
peptic ulcer disease absent 
3.7.1.2. Previous PUD and endoscopic diagnosis of peptic ulcer 
A history of previous peptic ulcer disease was not significantly associated with the 
endoscopic diagnosis. 
Though the RR was 1.35, history of previous peptic ulcer disease was not statistically 
significantly associated with endoscopically proven PUD as the 95% CI for the 
relative risk included I. However, this is more likely to be associated with endoscopic 
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diagnosis of PUD as lower CI (0.99) is almost equal to "1" and the upper CI (1.84) 
does not exclude an 84% increase in the relative risk. See table 7. 
Table 7: Significance of previous PUD on endoscopic diagnosis of peptic 
ulcer. 
PUD d on en oscopy 
+ve -ve Total RR 95% CI of RR P* 
Prev.PUD +ve 33 26 59 1.35 0.99-1.84 0.06 
Prev. PUD -ve 51 72 123 
Total 84 98 182 
*Chi square test; Prev.PUD +ve = prev. peptic ulcer disease present; Prev. PUD -ve = previous peptic 
ulcer disease absent. 
3.7.1.3. Ulcerogenic drugs (NSAID and salicylates) and outcome 
Current intake of NSAID and salicylates had no association with outcome (table 8). 
The RR 0.82; 95% CI, 0.58-1.17; p = 0.26. Though the RR was suggestive of a 
reduced likelihood of a good outcome, the 95% CI for the RR included 1 indicating 
that the association was not significant. 
Table 8: Association of ulcerogenic drug intake and outcome 
outcome 
Yes No Total RR 95% CI of RR P* 
Drugs 31 56 87 0.82 0.58 - 1.17 0.26 
No drugs 49 64 113 
Total 80 120 200 
*Chi-square test. Drugs refers to NSAID and sahcylates 
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• Drug history and proportion of endoscopic diagnosis of peptic ulcer 
The risk of finding a peptic ulcer at endoscopy was increased by 79% (95% CI 33%-
140%) in patients taking ulcerogenic drugs. The association between use of NS AID 
or salicylates with diagnosis of peptic ulcer disease is shown in table 9. 
Table 9: Association of ulcerogenic drug intake with a diagnosis of peptic 
ulcer. 
PUD d on en oscoov 
+ve -ve Total RR 95% CI of RR P* 
Drugs 55 32 87 1.79 1.33-2.40 <0.001 
No drugs 40 73 113 
Total 95 105 200 
*Chi-square test; PUD= peptic ulcer disease; Drugs refers to NSAID and salicylates 
• Drug history and Gastritis 
Forty-seven (23 .5%) were found to have gastritis on endoscopy. Of these, 16 (30.2%) 
were taking either NSAID or salicylates. 
Table 10: Association of ulcerogenic drug intake with gastritis. 
Gastritis 
Yes No Total RR 95% CI of RR P* 
Drugs 16 71 87 0.67 0.39 - 1.14 0.13 
No drugs 31 82 113 
Total 47 153 200 
*Chi-square test. Drugs refers to NSAID and salicylates 
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There was no association between ingestion ofNSAID or salicylates and the diagnosis 
of gastritis on endoscopy. The 95% CI did not exclude a 61 % reduction or 14% 
increase in development of gastritis in those taking ulcerogenic drugs (table 10). 
3.7.1.4. Warfarin intake and outcome 
Sixteen (80%) of the 20 patients taking warfarin to achieve anticoagulation, required 
blood transfusion. Six patients were transfused with fresh frozen plasma as well. 
Four (67%) of the six were on warfarin and 2 (33%) had deranged liver function. 
Significantly more patients on warfarin required blood transfusion compared to those 
not taking warfarin. See table 11. 
Table 11: Warfarin intake and transfusion requirements 
Blood transfusion 
yes no Total RR 95% CI of RR P* 
Warfarin 16 4 20 1.67 1.28-2.19 0.006 
No warfarin 86 94 180 
Total 102 98 200 
*Chi-square test 
3.7.1.5. Alcohol 
A history of alcohol intake was not associated with outcome. 
Alcohol binge had no association with outcome. The RR of 1.19 is suggestive of a 
weak association with a good outcome but the 95% CI for the RR indicates that this 
association was not significant. See table 12. In 5 patients information on alcohol 
binge drinking was not available. 
66 
CHAPTER 3: RESULTS 
Table 12: History of alcohol binge and outcome 
Outcome 
Good Poor Total RR 95% CI of RR P* 
Alcohol B +ve 19 22 41 1.19 0.81-1.75 0.39 
Alcohol B -ve 60 94 154 
Total 79 116 195 
*Chi square test; Alcohol B. = Alcohol binge 
Alcoholism had no association with outcome. The RR of 1.27 was suggestive of an 
association with a good outcome but the 95% CI for the RR indicates that the 
association was not significant. See table 13 . 
Table 13: History of alcoholism and outcome 
Outcome 
Good Poor Total OR 95% CI of OR P* 
Alcolism +ve 17 18 35 1.27 0.86-1.88 0.25 
Alcolism -ve 63 102 165 
Total 80 120 200 
*Chi square test; Alcohsm. = Alcohohsm 
3.7.1.6. Comorbid diseases and outcome 
• Cardiac disease 
Thirty-eight ( 19%) of the 200 patients had cardiac disease both on history and 
examination. Cardiac disease was significantly associated with outcome. Patients 
with cardiac disease were 53% less likely to have a good outcome. The 95% CI 
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indicates that these patients were 10 - 75% less likely to have a good outcome when 
compared to those without cardiac disease. See table 14. 
Table 14: Presence of cardiac disease and outcome 
Outcome 
Good Poor Total RR 95%CI ofRR P* 
Cardiac +ve 8 30 38 0.47 0.25:0.90 0.008 
Cardiac -ve 72 90 162 
Total 80 120 200 
*Chi square test; Cardiac +ve = presence of cardiac disease; Cardiac -ve =absence of cardiac disease 
• Renal disease and outcome 
Renal disease was not significantly associated with outcome. The RR showed a 73% 
reduction in the likelihood of a good outcome in those with renal disease but the 95% 
CI for the RR indicated that a 96% reduction to a 72% increase in the likelihood of a 
good outcome could not be excluded. (Note the small sample of those with renal 
disease) . See table 15. 
Table 15: Presence of renal disease and outcome 
Outcome 
Good Poor Total RR 95% CI of RR P* 
Renal +ve I 8 9 0.27 0.04-1.72 0.08 
Renal -ve 79 112 191 
Total 120 80 200 
*Chi square test ; Renal +ve = presence of renal disease; renal -ve = absence of renal disease 
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• Pulmonary disease and outcome 
Thirty ( 15%) of the 200 patients had signs of pulmonary disease on examination. 
Presence of pulmonary disease was not associated with outcome. The RR of O. 72 was 
suggestive of a 28% reduction in the likelihood of a good outcome in those with 
pulmonary disease. The 95% CI for the RR of 0.40-1.28, p=0.22 indicates that the 
association was not significant as it does not exclude a 60% reduction or a 28% 
increase in the likelihood of a good outcome. 
• Hepatic disease and outcome 
Hepatic disease was not associated with outcome. A RR of 1.27 is suggestive of an 
association with a good outcome but the 95% CI of 0.67-2.41; p = 0.51 indicates that 
the association was not significant. 
• Haematological disease and outcome 
The number of patients with haematological disease was too small for a meaningful 
statistical analysis. However, none of the 3 patients with haematological disease had a 
good outcome. They all required blood transfusion. Two were transfused 1-3 units of 
blood, while one was transfused at least 4 units of blood. None had endoscopic 
therapy or surgery and there were no deaths. 
• Neurological disease and outcome 
Presence of a central nervous system disease was not associated with outcome. The 
RR of 0.82 suggested that the likelihood of a good outcome was reduced but the 95% 
CI for the RR of 0.36-1.87, p = 0.76 indicates that the association was not significant. 
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• Musculoskeletal disease and outcome 
Presence of musculoskeletal disease was not associated with outcome. The RR of 
0.74 was suggestive of a 26% reduction in the likelihood of a good outcome but the 
95% CI for the RR of 0.41-1.36, p = 0.30 suggests that the association was not 
significant. 
• Comorbidity and outcome 
When all diseases (cardiac, pulmonary, renal, hepatic, haematological, neurological 
and musculoskeletal) were combined, the likelihood of a good outcome was reduced 
by 33% (6% - 52%) in patients with other underlying disease when compared to those 
with no other underlying disease. See table 16. 
Table 16: Association between comorbidity and outcome 
Outcome 
Good Poor Total RR 95% CI of RR P* 
Comorbid.+ve 41 81 122 0.67 0.48-0.94 0.02 
Comorbid -ve 39 39 78 
Total 80 120 200 
*Chi square test; Comorbid =comrbidity; 
3.7.1.7. Age and outcome 
Age was associated with outcome. Patients under the age of 60 years were 58% more 
likely to have a good outcome compared to those patients aged greater than 60 years. 
See table 17 
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Table 17: Association between age and outcome 
Outcome 
Good Poor Total RR 95% CI of OR P* 
Age < 60 yrs 52 56 108 1.58 1.10-2.28 0.01 
Age > 60 yrs 28 64 92 
Total 80 120 200 
*Chi square test 
Comorbidity increased with increasing age (RR 1.75; 95% CI, 1.39-2.20; p < 0.001) 
for those over the age of 60 years. 
3.7.1.8. History of melaena or haematemesis and outcome. 
Presentation with haematemesis alone was associated with good outcome. The 
likelihood of a good outcome was 72% higher in those who presented with 
haematemesis alone when compared to those who presented with melaena alone. See 
table 18. 
Table 18: Influence of haematemesis on outcome 
Outcome 
Good Poor Total OR 95% CI of OR P* 
Haemat. +ve 59 65 124 1.72 1.14-2.59 0.005 
Haemat. -ve 21 55 76 
Total 80 120 200 
*Chi square test; Haemat. +ve = positive history ofhaematemesis; Haemat. -ve = melaena 
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3.7.1.9. Haemodynamic assessment and outcome 
Patients with a good outcome had significantly higher blood pressure, lower pulse rate 
and higher haemoglobin levels compared with those with a poor outcome. See table 
19. 
Table 19: Haemodynamic assessment and outcome 
outcome 
Good Poor p 
Systolic BP; median, 135 (120-159) 120 (105-140) 0.002 
(I-Q range) 
Pulse; median, (I-Q 86 (80-100) 100 (90-110) <0.0001 
range) 
Hb (median, I-Q range) 13 (10.8-14) 8 (5.5-10.5) 0.0001 
1-Q range = interquartile range 
Though the results show a difference in systolic blood pressure, pulse and 
haemoglobin between those who had a good outcome and those who had a poor 
outcome, there were no clear-cut values separating these two groups except for 
haemoglobin that shows a cut-off of below 8 gm/dl. See figures 4-6. 
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On bivariate analysis haemoglobin greater than 10 g/dl (RR 10.5; 95% CI, 4.8-23 = < 
0.001), pulse rate less than 100 beats per minute (RR 1.76; 95% CI, 1.18-2.6; p = 
0.003) and systolic blood pressure greater than 100 mm Hg (RR 4.58; 95% CI, 1.2-
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variables, an increase in blood pressure was associated with good outcome (OR 1.01 
for each unit increase in systolic blood pressure (mm Hg); 95% CI, 1.0-1.02; p= 
0.016 and increase in pulse rate was associated with poor outcome (OR 0.97 for each 
unit increase in pulse rate per minute; 95% CI, 0.95-0.99; p= 0.0006). 
3.7.1.10 Pre-syncope or syncope and haemodynamic assessment 
One hundred and six (53%) of the patients had symptoms of pre-syncope or syncope. 
Significantly more patients presenting with syncope or pre-syncope had a pulse rate 
greater than 100 beats per minute and haemoglobin less than 10 g/dl while the 
proportion presenting with blood pressure less 100 mm Hg was not significantly 
different. 
There was a very significant association between presentation with syncope and the 
level of haemoglobin. The risk of syncope was increased in those who had 
haemoglobin less than 10 g/dl. The association between syncope and pulse rate of 
greater than 100 beats per minute or systolic blood pressure of less than 100 mm Hg 
closely approached significance. See tables 20-22. 
Table 20: Association between pre-syncope or syncope and haemoglobin 
s ,vncope 
Hb g/dl Yes No Total P* 
<10 60 32 92 0.002 
>10 46 62 108 
Total 106 94 200 
* Chi square test 
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Table 21: Association between pre-syncope or syncope and pulse rate 
Syncope 
Pulse b/min Yes No Total P* 
>1 00 49 31 80 0.056 
<100 57 63 120 
Total 106 94 200 
* Chi square test 
Table 22: Association between pre-syncope or syncope and blood pressure 
s ivncooe 
BP mm Hg Yes No Total P* 
<100 6 15 21 0.07 
>JOO 88 91 179 
Total 94 106 200 
* Chi square test 
3.7.1.11. Syncope and outcome 
Presentation with pre-syncope or syncope was significantly associated with outcome. 
Patients presenting with pre-syncope or syncope were 57% (38% - 71 %) less likely to 





* Chi square test 
Association between pre-syncope or syncope and outcome 
Outcome 
Yes No Total RR 95% CI of RR P* 
26 80 106 0.43 0.29- 0.62 <0.0001 
54 40 94 
80 120 200 
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3.7.1.12. Postural blood pressure and outcome 
The presence of a postural drop in blood pressure was recorded in 136 of the patients. 
Postural drop in blood pressure at presentation was not associated with outcome. The 
95% CI for the RR included 1. See table 24. 
Table 24: Relationship of postural hypotension to outcome 
Outcome 
Good Poor Total RR 95% CI of RR P* 
Post. hypo.+ve 12 13 25 1.09 0.69-1.72 0.72 
Post. hypo. -ve 49 62 111 
Total 61 75 136 
*Chi square test; Post. hypo. = Postural hypotension (postural drop in blood pressure). 
3.7.1.13. Shock on presentation and outcome 
All but 1 of the 11 patients presenting with shock (blood pressure < 100 mm Hg and 
pulse > 100 beats/min) and all but 1 of the 10 patients presenting with blood pressure 
less than 100 mm Hg and pulse less than 100 per minute received blood transfusion. 
Presentation with shock was associated with poor outcome. This association remained 
significant after inclusion of patients who had blood pressure less than 100 mm Hg 
but normal pulse rate ( < 100 beats per minute). See table 25. 
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Table 25: Relationship of shock to outcome 
Outcome 
Good Poor Total RR 95% CI of RR P* 
Shock +ve 2 19 0.22 0.06-0.83 0.002 
Shock-ve 79 110 
Total 
*Chi square test; +ve= Presence; -ve = absence of shock at presentation 
Summary of the Bivariate analysis 
The bivariate analysis showed that all variables except NSAID, salicylates, alcohol, 
previous peptic ulcer disease, comorbidities (renal, pulmonary, hepatic, neurological 
and musculoskeletal) when analysed individually, and postural hypotension were 
predictors of outcome at the 5% level of significance. 
3.7.2. Multivariate analysis 
Tables 26 and 27 show all variables entered into a multiple logistic regression model 
and show the combination of variables that was associated the closest with good 
outcome, after controlling for confounders. Continuous variables (haemoglobin, 






Predictors of good outcome (no transfusion, no endoscopic therapy 
no surgery and alive at 1 month) (multiple logistic regression) 
*AIC for the model =147.7 Full model 
Variable Parameter SE Odds Ratio 95%CI P value 
Estimate 
No melaena 1.66020 0.68887 5.26 1.35 -20.53 0.01 
No -0.02864 0.59433 0.96 0.3-3.1 0.96 
haematemesis 
No syncope 1.239209 0.492880 3.45 1.3-9.1 0.01 
No NSAID 0.283486 0.600553 1.33 0.41 -4.35 0.64 
No Salicylate 0.524279 0.52 1431 1.69 0.60-4.74 0.31 
No Previous 0.444832 0.528617 1.56 0.54-4.43 0.40 
PUD 
No warfarin -0.33172 0.98839 0.72 0.10-5.1 0.74 
HB > JO g/dl 3.07708 0.61554 21 .69 6.43 - 73.25 <0.0001 
Pulse b/min -0.02125 0.01623 0.98 0.94- 1.01 0.19 
BP mm Hg 0.00756 0.00885 1.0 0.99- 1.03 0.39 
Age < 60 years 0.153419 0.564174 1.17 0.38 - 3.56 0.78 
No comorbidity 0.095521 0.553404 I.I 0.37 - 3.29 0.86 
SE= standard error; *AIC = Akaike ' s Information Criterion (see definition) 
With haemoglobin and age as categorical variables and pulse and blood pressure as continuous 
variables. 
Haemoglobin and age were entered as categorical variables because they were not 
accepted into the model as continuous variables . 
• 
3. 7.2.1. Predictors of good outcome (no transfusion, no endoscopic therapy, 
no surgery and alive at one month) (multiple logistic regression). 
All variables were entered into a multiple logistic regression model with continuous 
variables entered as categorical variables using pre-determined cut-off values. This 
was done to test whether the result would be different when continuous variables were 





Predictors of good outcome (no transfusion, no endoscopic therapy, 
no surgery and alive at one month) (multiple logistic regression). 
AIC for the model= 146.8 Full model 
Variable Parameter SE Odds Ratio 95%CI P value 
Estimate 
No melaena 1.65034 0.67878 5.2 1 1.36-19.93 0.01 
No -0.03461 0.59676 0.96 0.29-3.1 0.95 
haematemesis 
No syncope 1.33823 0.49249 3.8 1.44- 10.09 0.006 
No NSAID 0.33823 0.593162 1.39 0.43 -4.5 0.57 
No Salicylate 0.548433 0.522767 1.73 0.61 -4.86 0.29 
No Previous 0.596731 0.548508 1.81 0.61-5.37 0.27 
PUD 
No warfarin -0.27043 0.97533 0.76 0.11 -5.25 0.78 
HB > JO g/dl 3.13403 0.61192 22.97 6.85 - 76.98 <0.0001 
Pulse < 100 0.862019 0.555835 2.37 0.78-7.1 0.12 
b/min 
BP > JOO mm 0.90916 1.00267 2.48 0.34- 18.01 0.36 
Hg 
Age < 60 years 0.09078 0.56496 1.09 0.36- 3.35 .87 
No comorbidity 0.02899 0.56359 1.03 0.34 - 3.14 0.95 
SE = standard error. With haemoglobin, pulse, blood pressure and age as categorical variables. 
In both full models, whether variables were used as continuous or categorical, absence 
of melaena, absence of syncope and haemoglobin value of> 10 g/dl were significant 
in_ predicting a good outcome. The strength of associations (i.e. p values) were also 
very similar in the 2 models . 
3.7.2.2. Stepwise selection of the final model 
Using stepwise logistic regression with an inclusion criterion of p = 0.10 and retention 
criterion of p = 0.05 a final model was selected. This was done in order to select the 
best predictive variables and assess their interaction once all variables not 
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significantly associated with outcome were excluded. Age, haemoglobin, pulse and 
blood pressure were entered as categorical variables. 
The final model had absence of melaena, haemoglobin greater than 10 g/dl and 
absence of syncope as predictors of good outcome. See table 28. 
The last 2 variables to leave the model were absence of previous history of peptic 
ulcer disease (p = 0.1) and pulse of< 100 beats/min (p = 0.07) respectively. 
Table 28: Final Model: Predictors of a good outcome 
AIC for the model= 139.0 
Variable SE z P value OR 95% Cl for OR 
No melaena 2.429009 3.115 0.002 4.8 1.79 - 12.94 
HB > lOg/dl 14.01974 5.995 <0.0001 25.8 8.9- 74.8 
No Syncope 1.762506 3.120 0.002 3.98 1.67 - 9.48 
This model has sensitivity for good outcome of 34% (27-40%), specificity of 98% 
(95-100%), positive predictive value of 90% (86-94%) and negative predictive value 
of 69% (62-75%). The LR+ was 13.5 (5.3-54) and LR" was 0.68 (0.57-0.79). With 
this model 72% of the patients were correctly classified. Table 29 shows 2x2 t-.ibles 
for the model. 
Table 29: 2x2 table for final model (no melaena, no syncope, Hb> 10 g/dl) 
Outcome 
Good Poor Total 
All three variables 27 3 30 
~ 2 variables 53 117 170 
Total 80 120 200 
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A model combining any 2 of the 3 variables had sensitivity for good outcome of 74% 
(68-80%), specificity of 83% (78-88%), positive predictive value of 75% (69-81 %) 
and negative predictive value of 83% (77-88%). The LR+ was 4.4 (2.8-6.6) and LK 
was 0.32 (0.21-0.45). With this model 79.5% of the patients were correctly classified. 
Table 30 shows 2x2 tables for the model. 
Table 30: 2x2 table for a combination of any 2 of the 3 variables 
Outcome 
Good Poor Total 
Combination of any 2 59 20 79 
variables 
< 2 variables 21 JOO 121 
Total 80 120 200 
With this model more patients were correctly classified and it had a higher sensitivity 
but the specificity was lower than the model combining all 3 variables. 
3.7.2.3. Multiple logistic regression analysis with age, haemoglobin, pulse 
and blood pressure as continuous variables. 
When the variables (age, haemoglobin, pulse and blood pressure) entered the model as 
continuous variables rather than categorical variables, the final model had 
haemoglobin p = <0.0001 , pulse (p = 0.041) and absence of syncope (p = 0.003) as 
predictors of good outcome. See table 31. The last 2 variables to leave the model 








Final model: predictors of good outcome (pulse and haemoglobin) 
as continuous variables. 
SE z P value OR 95% CI for OR 
0.2123625 6.315 <0.0001 1.97 1.59 - 2.44 
0.0142896 -2.047 0.041 0.97 0.94- 0.99 
1.921189 2.990 0.003 4.08 1.62- 10.27 
The model where all variables were categorical was used for simplicity of 
implementation in clinical practice. 
3.8 Test characteristics of different combinations of variables that were 
significant in predicting a good outcome. 
Table 32 shows a summary of sensitivity, specificity, positive predictive value, 
negative predictive value and their 95% CI, percentage of patients correctly classified, 
the likelihood ratio for a positive test and likelihood ratio for a negative test and 95% 



































































































































































































































































































































































































































































































































































































































































































































































































































A graphic representation of True Positive Rates (sensitivity) and 
False Positive Rates (I-Specificity) for different combinations of 
predictor variables 
• (Hb>) 




• • (Mel) 
(Mel+syc) 




0 4 8 12 16 20 24 28 32 36 40 44 48 52 
100-SPECIFICITY 
Hb> = Haemoglobin > I Og/dl; Mel. = No melaena; Syc. = No syncope; any 2 = combination of any 2 of 
the 3 variables 
Figure 7 shows that the model with all the three variables (Hb> 10 g/dl, absence of 
melaena and absence of syncope) had the highest specificity but a low sensitivity. 
3.9 Models with additional variables 
The last three variables to leave the model were BP > 100 mm Hg (p = 0.124), history 
of previous peptic ulcer disease (p = 0.103) and pulse < 100 beats/min (p = 0.076). 
Tables 33 and 34 show models that included these variables. 
86 
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• Predictors of good outcome (no transfusion, no endoscopic therapy, no 
surgery and alive at 1 month) (multiple logistic regression) 
Pulse rate as a categorical variable was included in the model because it had the 
lowest p value of the excluded variables. 
Table 33: No melaena, no syncope, Hb > 10 g/dl and pulse<lOO b/min 
(multiple logistic regression) 
AIC for the model= 137.5 
Variable Parameter SE Odds 95%CI P value 
Estimate Ratio 
No melaena 1.70407 0.57198 5.49 1.77 - 17.01 0.003* 
No syncope 1.308161 0.473578 3.69 1.45 - 9.43 0.006* 
Hb> lO g/dl 3.08298 0.491782 21.8 7.15 - 66.59 <0.0001 * 
Pulse< 100 b/min 0.620391 0.491782 1.8 0.7 -4.9 0.207 
SE = standard error; pulse, haemoglobin and blood pressure as categorical variables 
This model has sensitivity for good outcome of 26% (20-32%), specificity of 98% 
(95-100%), positive predictive value of 88% (83-92%) and negative predictive value 
of 66% (60-73%). The LR+ was 10.5 (4.0-42) and LR- was 0.76 (0.66-0.86). This 
model was not as good a predictor of outcome as the final model (no syncope, no 
melaena and Hb >IO g/dl). The model correctly classified 69% of the patients 
compared to 72% with the final model. 
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• Predictors of good outcome (no transfusion, no endoscopic therapy no 
surgery and alive at 1 month) (multiple logistic regression) 
Pulse as a categorical variable and previous peptic ulcer disease were included in this 
model because they had the lowest p values of the variables excluded from the final 
model. See table 34. 
Table 34: No melaena, no syncope, no previous PUD, Hb >10 g/dl and 
pulse<l 00 b/min (multiple logistic regression) 
AIC for the model= 137.1 
Variable Parameter SE Odds 95%CI P value 
Estimate Ratio 
No melaena 1.311646 0.463938 3.7 1.49-9.27 0.005* 
No syncope 1.167762 0.407117 3.2 1.44-7.17 0.004* 
Hb> lO g/dl 3.19514 0.49489 24.4 9.2 - 64.7 <0.0001 * 
Pulse < 100 b/min 0.548248 0.422089 1.73 0.75 - 3.97 0.194 
No Previous PUD -0.081511 0.084544 0.92 0.78 - 1.09 0.334 
SE = standard error; PUD = previous peptic ulcer disease 
This model had sensitivity for good outcome of 16% ( 11-21 % ), specificity of 99% 
(98-100%), positive predictive value of 93% (89-96%) and negative predictive value 
of 64% (57-71%). The LR+ was 19.5 (10-25) and LR- of 0.84 (0.76-1.07). With this 
model 66% of the patients were correctly classified. This combination of variables 
has a higher specificity and LR +ve than all the other models but sensitivity and 
negative predictive values were very low compared to other models. 
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4.1 DISCUSSION 
This prospective study was undertaken to find predictors of good outcome 
(i.e. no transfusion or endotherapy or surgery and alive at one month) in 
patients presenting with upper gastrointestinal bleeding, with a view to 
identifying criteria for the selection of patients who will recover without 
interventions requiring endoscopy. Since availability of endoscopy is limited 
in our setting, there is a need to select those patients who would benefit from 
it the most, i.e. those in whom it could not only help establish the source of 
bleeding but also change management decision. 
4.1.1 Endpoints 
Blood transfusion was taken to be a poor outcome event because it requires 
admission to hospital, laboratory, medical and nursing expertise. The need for 
blood transfusion implies significant bleeding and possible need for 
endotherapy or surgical intervention to control bleeding. Endotherapy and 
surgery both require the services of a trained specialist. These latter services 
are available at only some secondary and at no primary level hospitals. 
Hence, all patients with UGIB requiring such interventions need to be referred 
to centres where facilities are available for endoscopy, endotherapy, and 
surgery. 
Death is the end point that we all strive to reduce. 
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4.1.2. Patient Characteristics 
• Age and gender 
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Our study population had a median age of 57.5 years (interquartile range 43 .7-
71.4) and a male preponderance. This is consistent with findings from other 
studies (Longstreth 1995 and 1998, Silverstein 1981 ). 
The finding reflects an increase in the age of patients presenting with upper 
gastrointestinal bleeding over the past 50 years as reported.by Allan and 
Dykes in 1976, that the percentage of patients over the age of 60 years had 
increased from 2% - 48%. Gustavsson et al. (1988) also reflected a rise in 
median age of patients from 51 .5 to 64.5 over a 30-year period (1956-1985). 
• Mode of presentation 
More patients presented with melaena alone (76, 38%) or with both melaena 
and haematemesis (70, 35%) than with haematemesis alone (54, 27%). This 
is in agreement with a study by Terdiman et al (1997) that had a similar age 
distribution and found similar proportions in the mode of presentation. 
• Positive Faecal Occult Blood (FOB) Test 
Patients presenting with haematemesis alone may have a negative FOB test 
because of the transit time before blood reaches the rectum (Rockey 1999). 
Of the patients that had a FOB test done, not surprisingly a higher proportion 
of patients presenting with melaena { 121 (94.5%) of 128 patients} had a 
positive FOB test compared to 25 (61%) of the 41 patients presenting with 
haematemesis alone. 
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4.1.3. Potential Risk Factors identified on Clinical Assessment and 
Outcome 
• History of previous peptic ulcer disease and outcome 
Previous history of peptic ulcer disease did not predict outcome. These results 
are consistent with the results of previous studies. Katschinski et al. ( 1994) 
found no association between history of previous peptic ulcer disease and 
rebleed or death. Similarly, Jaramillo (1994) found no association between 
past history of peptic ulcer and prediction of further haemorrhage. Likewise 
Corley (1998) found that history of previous peptic ulcer disease was not a 
predictor of outcome. 
A few studies have reported a higher mortality rate in first time bleeders as 
compared to those with previous history of peptic ulcer disease (Hasselgren 
1998, Braniski 1990, Schiller 1970, Johnson 1973 ). 
Hasselgren (1998) argued that patients with previous peptic ulcer disease 
represent a separate group with chronic disease and a low case-fatality rate. 
Schiller ( 1970) pointed out that decisions in the management of patients could 
not be based on whether or not they have had previous peptic ulcer disease, as 
this is a poor predictor of outcome. The findings of this study support this 
view. 
• Association between history of NSAID intake and Endoscopic 
Diagnosis of Peptic Ulcer. 
The risk of finding a peptic ulcer at endoscopy was higher in patients taking 
NSAID or salicylates (RR 1.79; 95% Cl, 1.33 - 2.40; p < 0.001). These 
findings are in keeping with the general consensus that the use ofNSAID 
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increases the risk of peptic ulcer occurrence, ulcer complication (haemorrhage 
or perforation) and death by a factor of between 2 and 4 (Carson 1987, Griffin 
1988, Jick 1987). Nevertheless in our study, though current intake of 
ulcerogenic drugs was associated with an increased risk of peptic ulcer 
disease, it was not significantly associated with outcome (RR 0.82; 95% CI, 
0.58-1.17; p = 0.26). The RR suggests association with poor outcome, a 
lower 95% CI of 0.58 includes a clinically meaningful association, but with 
our sample size we cannot say whether there is a meaningful association as 
the upper 95% CI does not exclude a 17% chance of good outcome. This 
might be due to inclusion of patients on minimal doses of NSAID; 
information on dosage and duration of intake was not collected. Case-control 
studies have found the increased risk of upper gastrointestinal bleeding in 
patients taking NSAID to have a linear dose-response relationship (Carson et 
al. 1987 and Henry et. al. 1993). 
• Warfarin and outcome 
Our study showed that significantly more patients who were taking warfarin 
required blood transfusion (RR 1.67; 95% CI, 1.28 - 2.19; p 0.006). 
Anticoagulation will increase bleeding as it causes coagulopathy. Warfarin 
itself has no known causative role in peptic ulcer disease. Though it increases 
bleeding in patients with peptic ulcers, placebo-controlled trials that excluded 
patients with known ulcer disease, have not documented a significant increase 
in bleeding ulcers (Laine 1994). 
Rockall et al. (1996) did not find anticoagulation to be a significant predictor 
of mortality. However anticoagulation has been used in patient selection. In 
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studies that selected patients with UGIB for outpatient treatment, or low 
intensity care, one of the requirements was that the patient was not on 
anticoagulants (Longstreth 1995, Kollef 1995). 
• Alcohol and outcome 
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The severity of mucosa! damage by alcohol is directly related to the local 
ethanol concentration and length of exposure (Domschke 1984). This results 
in inflammation of the stomach (gastritis) and of the oesophagus 
(oesophagitis). Both gastritis and oesophagitis can present as UGIB. Chronic 
heavy drinking if associated with violent vomiting can produce a Mallory-
Weiss tear (longitudinal tear at the gastro-oesophageal junction), which 
presents as UGIB. 
We found no association between alcohol intake and outcome. The results 
were similar for those who gave history of alcohol binge and those who gave 
history of alcoholism, (RR 1.19; 95% CI, 0.81-1.75; p = 0.39) and (RR 1.27; 
95% CI, 0.86-1.88; p = 0.25) respectively. The confidence intervals for both 
estimates include a greater than 50% increase in the chance of a good 
outcome. A weakness of our study is that we did not quantify the amount of 
alcohol consumed. It is possible that this obscured the effect of alcohol on 
outcome, but it should be noted that those who gave history of chronic 
alcoholism were analysed separately and still there was no significant 
association with outcome. 
The rate of peptic ulcer disease was significantly lower in those with a history 
of alcohol binge or alcoholism. History of alcohol binge or alcoholism 
appeared to reduce the likelihood of finding of peptic ulcer at endoscopy (RR 
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0.56; 95% CI, 0.34-0.92; p = 0.007 and RR 0.62; 95% CI, 0.37-1.03; p = 0.05 
respectively). There was no association between gastritis and alcohol binge 
(RR 1.48; 95% CI, 0.86-2.54; p = 0.16) or alcoholism (RR 1.62; 95% CI, 
0.94-2.79; p = 0.09). 
Ostensen et al. (1985) in a case-control study found an increased alcohol 
intake in controls as compared to cases with peptic ulcer. In this study the 
amount of alcohol taken was not quantified. It is possible that the cases 
modified their habits due to symptoms. 
Kelly (1995) found a significant association between alcohol intake and the 
risk of peptic ulcer disease after controlling for potential confounders such as 
smoking and NSAID. Compared to drinkers ofless than one drink per week, 
the relative risks among other current drinkers ranged from 0.8 for 1-6 drinks 
per week to 6.3 for more than 35 drinks. 
In contrast other authors have argued that complications of alcohol such as 
hepatic cirrhosis and portal hypertensive gastropathy increase incidence of 
peptic ulcer and UGIB. But this association is probably related to cirrhosis 
rather than to alcohol (Langman 1976). 
• Comorbidity and outcome 
Active comorbidity must be identified, and treated energetically at an early 
stage, in patients admitted with acute upper gastrointestinal bleeding. This is 
because most people who die following UGIB have significant comorbidity 
putting them at risk of decompensation of their comorbid disease and of post-
operative complications in the event that they have to undergo surgery (Wara 
1983, Terdiman 1998). 
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On bivariate analysis we found comorbidity to be a predictor of poor outcome 
(RR 0.67; 95% CI, 0.48-0.94; p = 0.02). However this association was lost 
on multivariate analysis. 
When the underlying diseases were analysed individually only cardiac disease 
was found to be associated with poor outcome (RR 0.47; 95% CI, 0.25-0.90; 
p= 0.008). Pulmonary, renal, hepatic, haematological, neurological and 
musculoskeletal diseases were not individually associated with outcome. The 
small number of patients with a particular comorbidity however, resulted in 
wide confidence intervals. 
In a study by Rockall et al. 1996, hepatic (OR 8.6) and renal disease (OR 
10.3) were most predictive of adverse outcome. Hepatic disease was not 
associated with outcome in our study but it must be noted that the number of 
patients with hepatic disease was small (10, 5%). Five were known to have 
liver cirrhosis, one had breast cancer with liver metastasis and the remaining 4 
were reported as having a palpable liver, which does not necessarily indicate 
active liver disease. It must be emphasised that patients with a known history 
of portal hypertension and varices were excluded from the study, thus 
reducing the number of patients in the sample with liver disease. 
Renal failure was not a predictor of outcome as very few patients (9, 4.5%) 
had renal failure. This number was insufficient for meaningful analysis, but 
despite this only one out of the nine had a good outcome. The wide 
confidence intervals (RR= 0.27; Cl, 0.04-1.72) include the plausible 
possibility of a meaningful association. 
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The role of comorbidity as a predictor of adverse outcome has been confirmed 
in other studies (Silverstein and ASGE 1981, Braniski et al. 1990, Kollef et al. 
1997) 
However, some studies have found comorbidity not to be a significant 
predictor of outcome. Wara et al. ( 1985) examined predictors of major 
haemorrhage. Cormobidity was recorded only if it predated the bleed and 
required specific treatment. Cormorbidity was found in 65% of both the self-
limited and the major haemorrhage groups. Jaramillo et al. (1994) looked at 
predictors of further haemorrhage in 567 patients. Comorbidity was a 
significant predictor on bivariate but not on multivariate analysis. Clason et 
al. ( 1986) examined 326 admissions prospectively to predict factors of further 
haemorrhage or mortality. Though comorbidity was a significant predictor on 
bivariate analysis, this was lost on multivariate analysis. 
Corley et al. ( 1998) stratified 3 3 5 patients into good outcome ( discharged 
alive, no surgery and no persistent or recurrent haemorrhage) and adverse 
outcome (patients with any of the above factors) . On bivariate analysis 
comorbidity was a significant predictor of adverse outcome but on 
multivariate analysis only evidence of portal hypertension was a predictor of 
poor outcome. 
In these studies, comorbidity lost significance on multivariate logistic 
regression analysis presumably because of the association of comorbidity with 
other risk factors for poor outcome. Once the multivariate model adjusted for 
these other variables, no independent association with comorbidity persisted. 
Most studies have however confirmed the significant role of active 
co morbidity in predicting poor outcome. In the study by Rockall et al. ( 1996), 
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presence or absence of comorbidity is one of the risk factors used in the 
scoring system they devised to predict outcome. 
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Longstreth et al. (1998) used a number of criteria to select patients for 
outpatient treatment using absence of active comorbidity as one of the factors. 
They selected 176 patients for outpatient care who on follow-up for a period 
of 6-26.8 months had 0% mortality, 1 % recurrent bleeding and 1 % 
hospitalisation. 
• Age and outcome 
Many other studies have found age to be significantly associated with adverse 
outcome (Rockall 1996, Morgan 1988, Zimmerman 1995, Katschinski 1994, 
Jaramillo 1994, Clason 1986, Longstrethl 995). Advancing age in the 
population of patients presenting with UGIB has been blamed for lack of 
improvement in mortality rate despite diagnostic and therapeutic 
improvements. This is because there is an increase in concomitant disease 
with increasing age (Herstad 1982, Wara 1983). 
We found an increased risk of comorbidity in those over the age of 60 years 
when compared to patients below this age. (RR 1.75; 95% CI, 1.39-2.20; p < 
0.001). 
On bivariate analysis age was a predictor of outcome. Patients less than 60 
years old had a better outcome than those over the age of 60 years, (RR 1.58; 
95% CI, 1.10-28; p=0.01 ). This was similar to findings from previous studies 
that identified low risk patients with upper gastrointestinal haemorrhage 
(Bordley et al. 1985, Rockall et al. 1996). 
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On multivariate logistic regression analysis, however, age was not a predictor 
of outcome. This reflects to findings from previous studies (Wara et. al. 1983, 
Corley et al. 1998, Turner et al. 1991, Northfield et al. 1971, Chojkier et. al. 
1986) and could be explained by the adjustment for other variables such as 
comorbidity in the multivariate model. However, in this study both age and 
comorbidity were not associated with outcome on multiple logistic regression 
analysis suggesting that they were both associated with identified predictors 
(haemoglobin concentration, syncope and melaena) 
• Mode of presentation (haematemesis, melaena or both) and outcome 
On bivariate analysis haematemesis alone was associated with good outcome 
(RR 1.72; 95% CI, 1.14-2.59; p = 0.005 while presentation with melaena 
alone (RR 0.58; 95% CI, 0.39-0.87; p <0.005) was associated with a poor 
outcome. This is unlike findings in most studies where haematemesis is 
associated with an adverse outcome (Terdiman 1997, Wara 1985, Jaramillo 
1994, Silverstein et. al and ASGE 1981, Northfield 1971 and Schiller 1970). 
Schiller et al. ( 1970) had a fatality rate of 12% in those who presented with 
haematemesis, 5.4% in those who presented with melaena and 9.4% in those 
who presented with both haematemesis and melaena. 
Wara et al. (1985) recommended from their study that patients presenting with 
haematemesis and melaena or haematemesis alone should have endoscopy as 
the risk of massive haemorrhage is increased. 
Silverstein and the National ASGE found that presence of haematemesis with 
any stool colour, whether melaena or not, had an average mortality rate of 
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20. 7%, in absence of haem~temesis mortality was 6.6% but rose to 11. 7% in 
the presence of history of coffee ground vomiting. 
In the study by Northfield (1971), the rate ofrebleed was 20% in patients 
presenting with haematemesis and 3% in those presenting with melaena. 
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The difficulty in comparing these studies with our study is that all these 
studies included patients with varices who tend to present with haematemesis 
and are at high risk of a poor outcome. 
The other problem is that the end points differ in the different studies. 
We included blood transfusion as part of the poor outcome measures. Patients 
presenting with melaena alone tend to present late to hospital, as the bleeding 
is less brisk and less alarming. Therefore, they present with much lower 
haemoglobin levels and need blood transfusion. However, there are studies 
that have found the presence of melaena to be a predictor of an adverse 
outcome. Katschinski et al. (1994 ), in a study of 2217 patients, showed that 
melaena (OR 1.6; 95% CI, 1.1-2.4) was a predictor for rebleeding. Macleod 
et.al. (1982), in a study of 389 consecutive patients with UGIB, found that 
patients presenting with melaena or with both haematemesis and melaena 
were at greater risk o~ further haemorrhage compared to those presenting with 
haematemesis alone. 
A weakness of our study is that haematemesis included both patients with red 
haematemesis and with coffee ground vomit, the former being associated with 
brisker UGIB. It is possible that if these were analysed separately the 
association with outcome would have been different (Silverstein et. al and 
ASGE 1981 ). The other weakness is that haematemesis was not always 
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witnessed in hospital but obtained from history. This might not have always 
been reliable. 
• Pre-syncope or Syncope and outcome 
Patients presenting with pre-syncope or syncope had significantly lower 
haemoglobin (RR 1.5; 95% Cl, 1.17- 2.0; p = 0.001) than those who did not 
have these symptoms. Pulse rate (RR 1.29; 95% CI, 1.0-1.67; p = 0.056) and 
systolic blood pressure (RR 0.58 ; 95% CI, 0.29-1.16; p = 0.07) did not differ 
significantly between the two groups though the difference in pulse rate 
reached borderline significance. History of syncope was associated with poor 
outcome (RR 0.43 ; 95% Cl, 0.29- 0.62; p = < 0.001). 
Syncope is correlated with rapidity of blood loss. This variable has been 
incorporated as a predictor of outcome in very few studies. This is despite the 
fact that this information can easily be obtained on history at the time of 
presentation and that it costs nothing. 
Silverstein et al. (1981) and the National ASGE survey showed that syncope 
was not associated with high mortality rate or an increased incidence of 
complications but it was associated with blood transfusion> 5 units and 
surgery. Longstreth et al. (1995) using variables identified from a prior 
retrospective study, prospectively selected patients for treatment as 
outpatients. Of the patients managed as out-patients, 29% had history of 
syncope compared to 53% of those managed as in-patients. There were no 
deaths among the 34 patients who were treated as outpatients and only 1 
rebled. Zimmerman et al. (1995) did not find syncope to predict mortality 
(OR 2.6; 95% CI, 0.8-8.2; p = 0.114) but the trend is toward an association 
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with increased mortality, and the CI is very wide. Nevertheless, we cannot 
compare our findings to those of this study, as their only end point was 
mortality. They did not use transfusion requirements as an outcome measure. 
• Haemoglobin, Pulse and Blood Pressure and outcome 
Haemoglobin, pulse and blood pressure are all measures of severity of the 
bleed (Booker et. al. 1987). These variables have been used in many studies 
as predictors of outcome. 
We did not find clear-cut threshold levels between those who had a good 
outcome and those who had a poor outcome. However no patient with a 
haemoglobin level of less than 8 g/dl had a good outcome. This is artefactual, 
as the presence of low haemoglobin would dictate transfusion in our practice. 
For the purposes of our study, however, the aim of which was to identify 
criteria that indicated the patients that would not require urgent hospital 
admission and management, this was a relevant outcome. In the analysis we 
used internationally used cut-off levels for low risk of adverse outcome. 
Longstreth et al. 1995 in a retrospective study of 933 patients stratified 
patients into those who received outpatients and inpatient care. The cut-off 
values for pulse, haemoglobin and blood pressure for those who received out 
patient care were similar to those used in this study. 
In our study, on bivariate analysis haemoglobin greater than 10 g/dl (RR 10.5; 
95% CI, 4.8-23; p = < 0.001), pulse rate less than 100 beats/ minute (RR 
1.76; 95% CI, 1.18-2.6; p = 0.003) and systolic blood pressure of greater than 
100 mm Hg (RR 4.58; 95% Cl, 1.2-17.3; p = 0.002) were significantly 
associated with a good outcome. As continuous variables, a higher blood 
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pressure was associated with good outcome (OR 1.01 for each unit increase in 
systolic blood pressure (mm Hg); 95% CI, 1.0-1.02; p = 0.016) and increase 
in pulse rate was associated with poor outcome (OR 0.97 for each unit 
increase in pulse rate per minute; 95% CI, 0.95-0.99, p = 0.0006). On 
multiple logistic regression analysis, pulse rate and blood pressure lost 
statistical significance. This is probably due to association between pulse rate, 
blood pressure levels and haemoglobin value that was adjusted for in the 
multivariate model. 
Pulse rate and systolic blood pressure have been used in some studies to 
predict outcome. Rockall et al. (1996) used pulse and blood pressure in the 
model from which a risk score was generated. Bordley et al. (1985) stratified 
patients into high risk and low risk for poor outcome with systolic blood 
pressure of greater than 100 mm Hg being one of the six variables that were 
associated with good outcome. 
Turner et al. (1991) found no association between presence of shock (blood 
pressure <100 mm Hg and pulse rate >100 beats per minute), haemoglobin 
less than 10 g/dl on presentation and outcome. This study, like our study, 
excluded patients with varices. Similarly these variables did not predict the 
risk of major haemorrhage in a study by Wara et al. 1985, nor did they in the 
study by Perng C-L et al. (1994). 
This may be because in patients who are initially haemodynamically stable, 
but subsequently rebleed, the initial values of haemoglobin, pulse rate and 
blood pressure are poor predictors of major haemorrhage. 
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4.1.4 Multiple Logistic Regression analysis 
On bivariate analysis all predictor variables were significantly associated with 
outcome except current intake ofNSAID and/or, salicylates, history of 
ingestion of alcohol, previous peptic ulcer disease, comorbid conditions 
(renal, pulmonary, hepatic, haematological, neurological and musculoskeletal) 
when analysed individually and postural drop in blood pressure. Though 
ulcerogenic drugs were associated with increased incidence of peptic ulcer 
disease they did not predict outcome of UGIB. Multiple logistic regression 
analysis controlled for the effect of confounders. 
Absence of melaena, absence of syncope and haemoglobin greater than 1 Og/dl 
were the predictors of good outcome in our final model. Haemoglobin greater 
than 10g /dl (OR 25.8; 95% CI, 8.9-74.8; p = <0.001) was most significantly 
associated with outcome. As demonstrated in the scatter plots, no patient with 
a haemoglobin level of less than 8 g/dl had a good outcome, as this was an 
indication for transfusion. Melaena (OR 4.8; 95% CI, 1.8-12.4; p = 0.002) 
and syncope (OR 4.0; 95% CI, 1.7-9.5; p = 0.002) were similar in the strength 
of their association with outcome. A combination of two or of all three 
variables significantly improved the association. The improved specificity, 
predictive values and likelihood ratios of the combined variables demonstrate 
this. It must be emphasised that the good test characteristics shown by 
haemoglobin, as a single variable is artefactual as its presence determined 
transfusion. 
Further increasing the number of variables in the model did not improve its 
prediction of the outcome and the sensitivity decreased further. The final 
CHAPTER 4: DISCUSSION AND CONCLUSION 104 
model had slightly higher Akaike Information Criteria (AIC) than some of the 
models. In general, the smaller the value of this statistic the better the model 
and the fewer the number of variables the greater the clinical simplicity and 
usefulness. When unnecessary variables are added there is little change in the 
value or its value will increase (Collet 1994). However the AIC is only a 
guide for selecting the best set of predictors. 
4.1.5 Clinical relevance of the test characteristics 
• Likelihood ratios 
• Likelihood ratios (LRs) are measures of the accuracy with which a 
diagnostic test identifies its target disorder in an individual patient. They 
are regarded as the most useful indicators of test accuracy in a clinical 
context involving individual patients (Jaeschke 1994). The likelihood 
ratio represents the direction and magnitude of change from pre-test to 
post-test probability. The higher the ratio is above 1, the greater the 
change in probability in favour of the condition of interest, and the lower 
the ratio below 1 the greater the change in probability against the 
condition of interest. Ranges of ratios have had suggested clinical 
meaningfulness attached to them (Jaeschke 1994) as shown in the table 
35. 
Table 35: Magnitude of change to post-test probability of the disorder 
Shifts in the probability 
Conclusive 
Moderate 
Small (sometimes important) 
Small (rarely important) 
Ratio 
> 10 or <0.1 
5-IOor0. 1-0.2 
2-5 or 0.2-0.5 
1-2 or 0.5 -1.0 
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The LRs for the selected model were 13 .5 and 0.68 for positive and negative 
"tests" respectively. This suggests important usefulness of a positive test 
(haemoglobin > 10 g/dl, no syncope and no melaena) in identifying patients 
with good outcome but limited usefulness of a negative test in excluding a 
good outcome. Positive predictive value was 90% and negative predictive 
value was 69%. These values represent the post-test probabilities in a 
population with a 40% prevalence of good outcome. The predictive values of 
a test are influenced by the prevalence of the condition under study, so they 
are not applicable to populations with a different prevalence. 
• Sensitivity and specificity (Jaeschke 1994) 
Although LRs are more meaningful expressions of the clinical usefulness of a 
test for individual patients, sensitivity and specificity are more helpful in 
selecting tests for use in populations (such as our study sample). 
Sensitivity is the proportion of people with the target disorder in whom the 
test result is positive and specificity is the proportion of people without the 
disorder in whom the test is negative. The closer the proportion is to 1 the 
better the test. The sensitivity and specificity for good outcome for the test 
(final model) is 34% and 98% respectively, i.e. 66% false negatives and 2% 
false positives test (with good outcome as the condition of interest). In this 
clinical context the predictive test needs to have a high specificity for good 
outcome, thereby reducing the number of false positives (patients sent home 
wrongly) . A larger number of false negatives is more acceptable but at the 
cost of patients being kept in hospital who would have had a good outcome. 
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The alternative model that includes any two of the selected variables has 
unacceptably low specificity to be of clinical value. With a specificity of 
83%, 17% of patients whose management might have required urgent 
endoscopy would be sent home without endoscopy. 
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From table 32, it can be seen that the increase in specificity with the increase 
in the number of predictor variables is at such cost to sensitivity that it makes 
the prediction rule worthless in selecting anyone for management without 
urgent endoscopy. Therefore a further increase in the prediction variables 
above 3 would mean that the criteria would not alter current clinical practice. 
The investigator's judgement is that a predictive tool with a specificity of not 
less than 95% is acceptable. That is, no more than 5% of the patients with 
poor outcome should miss urgent endoscopy. Our predictive model meets 
these requirements as the specificity is 98%, and 95% CI (95-100). 
Of the 200 patients in our study, 30 (15%) satisfied the prediction rule 
(haemoglobin greater than IO g/dl, no melaena and no syncope). These would 
have been sent home without endoscopy. However, 3 of those who satisfied 
the prediction rule (1.5% of the total sample) had a poor outcome (see table 
29). Thus, with the prevalence of good outcome in this study, there would 
have been a 15% reduction in the number of urgent endoscopies. Sixty 
percent of all patients with UGIB, including 10% (3 of the 30) of those sent 
home without endoscopy had poor outcome. All 3 patients who were false 
positives according to the test criteria required sclerotherapy to control 
haemorrhage. They did not have blood transfusion or surgery, and were alive 
at one month. These patients presumably presented early with their bleed and 
thus did not to require transfusion. If the prediction rule were in practice they 
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would have been observed at a primary health care facility and referred at a 
later stage. 
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The predictor variables could be easily applied even in poorly resourced 
health centres, as they do not involve much expense or sophisticated 
equipment. Presence or absence of melaena can be objectively confirmed by 
rectal examination and haemoglobin values can be measured without much 
expense using a haemoglobinometer, and the symptom of syncope is easy to 
elicit as it involves transient loss of consciousness. The symptom of pre-
syncope is problematic, as it is subjective. 
It should be noted that these criteria help identify those who will get better 
anyway, regardless of endoscopy. It does not necessarily identify those who 
will benefit from endoscopy. 
4.1.6 Validation 
A clinical decision rule is "data driven" in that it is derived from a specific 
sample of patients. The test may not perform as well in a different population, 
and thus needs to be validated (Wasson 1985). The rule can be tested on the 
patients in the study from which the rule was derived ( cross-validation 
methods). Another approach is to test the prediction rule on a new group of 
patients in the same setting from which the rule was derived or from a 
different clinical environment. The preferable way is to embark on a second 
independent study in the same location, as this is a much more stringent test. 
None of these validations have been performed, given the constraints of time 
and patient numbers. 
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For the validation studies to be comparable, the protocol of the original 
researcher should be followed. Diagnostic and follow-up techniques should 
be rigorous. A co-ordinated prospective evaluation between original and 
subsequent investigators is preferable to numerous, poorly standardised 
attempts at validation. 
The most rigorous evaluation of the impact of these criteria on patient well 
being would be a randomised controlled trial of the effect on outcome of the 
use of the study criteria compared to performing endoscopy on everyone. 
4.1.7 Sample size and power 
Although some subgroups of the predictor variables (e.g. individual 
comorbidities) had too few patients to detect meaningful association with 
outcome, our sample was adequate to identify 3 predictors of high statistical 
significance. The confidence intervals for specificity for the selected model 
on a sample of 200 (95-100%) was sufficiently narrow to enable a decision to 
be made regarding acceptability of the test. This test however requires 
validation. If greater precision were required, the following would be the 
95% Cls for an estimated specificity of 98%: 96-99% with 400 patients, 96-
99% with 800 patients and 97- 99% with 1600 patients. Thus the 95% 
confidence interval would not change meaningfully with feasible increases in 
sample size. 
4.1.8 General applicability 
Patients included in the study are not representative of the population, 
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as patients who can afford private health care are cared for in private 
hospitals. Patients presenting to private hospitals with UGIB may be different 
at presentation from the study population in that they may present earlier, or 
they might have different degrees of exposure to risk factors for UGIB. Their 
outcome may differ due to different management strategies, such as 
transfusion practices. 
4.2 CONCLUSION 
• In this study absence of syncope, haemoglobin concentration greater 
than 10 g/dl and absence of a history of melaena were independent 
predictors of outcome. This is a test of good outcome regardless of 
endoscopy as findings post endoscopy were not included in its 
derivation. 
• The best predictive rule was a combination of all the 3 variables. 
• When this was used as a "test" for good outcome, the sensitivity was 
(34%) and specificity (98%). The likelihood ratios were 13.5 and 0.68 
for positive and negative tests respectively. These test characteristics 
indicate that the test was accurate at excluding poor outcome, which is 
a priority in the clinical context. The test was however not accurate at 
predicting good outcome. 
• The clinical implications of these findings are that the test would have 
resulted in a moderate impact on the reduction of unnecessary 
endoscopies (15% of admissions) with 5% or less of patients with poor 
outcome (1.5% of all patients) being sent home. In the judgement of 
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the investigator, this is an acceptable trade-off between benefits and 
costs. 
• The findings of this study may have clinical relevance, especially in 
under-resourced health care environment in which we practice. 
• The test however needs validation, preferably a second independent 
study in the same location, before being confidently applied to local 
practice. 
• The findings appear generalisable to similar patient populations. 
4.3 Future directions 
A validation study is required before these clinical prediction rules can be 




Allan Rand Dykes P. A study of the Factors Influencing Mortality Rates 
from Gastrointestinal Haemorrhage. Quarterly J. of Medicine 1976; 180: 533-
50. 
Altman DG, (ed). Practical statistics for Medical Research. Chapman & Hall ; 
1990: 396-435. 
American Heart Association. Report of a Subcommittee of the Postgraduate 
Education Committee. Recommendations of Human Blood Pressure 
Determination by Sphygmomanometers. Circulation 1967; 36: 980-988. 
Armstrong CP and Blower AL. Non-steroidal anti-inflammatory drugs and 
life threatening complications of peptic ulceration. Gut 1987; 28: 527-532. 
Asaki S. Efficacy of Endoscopic Pure Ethanol Injection Method for 
Gastrointestinal Ulcer Bleeding. World J. Surg. 2000; 24: 294-298 . 
Balanzo J, Villanueva C, Sainz Set al. Injection therapy of bleeding peptic 
ulcer. A prospective, randomised trial using epinephrine and thrombin. 
Endoscopy 1990; 22: 157-159. 
Basso N, Bagarani M, Bracci F et.al. Ranitidine and somatostatin. Their 
effects on bleeding from the upper gastrointestinal tract. Arch. Surg. 1986; 
121: 833-35. 
Berstad A. Management of acute upper gastrointestinal bleeding. Scand J. 
Gastroenterol. (Suppl. ) 1982; 75: 103-108. 
Bliss DW and Stabile BE. The impact of ulcerogenic drugs on surgery for 
treatment of peptic ulcer disease. Arch Surg. 1991 ; 126: 609-61 2. 
Booker JA, Johnson M, Booker C et. al. Pn,gnostic factors for continued or 
rebleeding and death from gastrointestinal haemorrhage in elderly. Age and 
Ageing 1987; 16: 208-214. 
Bordley DR, Mushlin Al, Dolan JG, Richardson WS, Barry M, Polio J and 
Griner PF. Early Clinical Signs Identify Low-Risk Patients with Acute Upper 
Gastrointestinal Haemorrhage. JAMA 1985; 253: 3282-3285. 
Braniski FJ, Coleman SY, Fouk PJ, Pritchett CJ, Fan S-T, Lai EC et al. 
Bleeding peptic ulcer: A Prospective Evaluation of Risk Factors for 
Rebleeding and Mortality. World J. Surg. 1990; 14: 262-269. 
Carson JL, Strom BL, Soper KA West SL and Morse ML: The Association of 
Non-Steroidal Anti-Inflammatory Drugs With Upper Gastrointestinal Tract 
Bleeding. Arch Intern Med. 1987; 147: 85-88. 
112 
Charlewood GP and Frylinck R. Some discrepancies in disease incidence 
between the European and the South African Negro (Bantu). S. Afr Med. J. 
1951; 25: 551-5. 
Chojkier M, Laine L, Conn HO and Lerner E. Predictors of Outcome in 
Massive Upper Gastrointestinal Haemorrhage. J. Clinical Gastroenterol. 
1986; 8(1): 16-22. 
Chung IK, Ham JS, Kim HS. Comparison of the haemostatic efficacy of the 
endoscopic hemoclip method with hypertonic saline-epinephrine injection and 
a combination of the two for the management of bleeding peptic ulcers. 
Gastrointestinal Endoscopy 1999; 49: 13-18. 
Chung SCS, Leung JWC, Sung JY, Lo KK et al. Injection or heat probe for 
bleeding peptic ulcer. Gastroenterology 1991; 100: 33-7. 
Clason AE, Macleod DAD and Elton RA. Clinical factors in the prediction of 
further haemorrhage or mortality in acute upper gastrointestinal haemorrhage. 
Br. J. Surg. 1986; 73: 985-987. 
Clements D, Aslan S, Foster D et al. Acute upper gastrointestinal haemorrhage 
in a district general hospital: audit of an agreed management policy. Journal of 
the Royal College of Physicians of London 1991; 25: 27-30. 
Collet D. ed. Strategy for model selection in Modelling Survival data. 
Chapman and Hall 1994:79. 
Cook JD, Guyatt GH, Salema BJ and Laine LA. Endoscopic Therapy for 
Acute Non-variceal Upper Gastrointestinal Haemorrhage: A Meta-analysis. 
Gastroenterol 1992; 102: 139-148. 
Corley D. A; Stefan AM, WolfM, Cook EF and Lee TH. Early Indicators of 
Prognosis in Upper Gastrointestinal Haemorrhage. Am J of Gastrc,enterol 
1998; 93 (3): 336-340. 
Coraggio F, Bertini G, Catalano A, Scarpato P, Gualdieri L. Clinical 
controlled trial of somatostatin with ranitidine and placebo in control of peptic 
ulcer haemorrhage of the upper gastrointestinal tract. Digestion 1989; 43 ( 4 ): 
190-195. 
Cutler JA and Mendeloff AI : Upper gastrointestinal bleeding: Nature and 
magnitude of the problem in the U.S. Dig Dis Sci 1981; 26 (7): 90s-96s. 
Daneshmend TK, Hawkey CJ, Langman MJS, Longan RF et.al. Omeprazole 
versus placebo for acute upper gastrointestinal bleeding: Randomised double-
blind controlled study. Br Med J 1992; 304: 143-147. 
De Dombal FT, Clarke JR, Clamp SE et.al. Prognostic factors in upper G.I. 
Bleeding. Endoscopy 1986; 18 (Suppl 2): 6-10. 
Domschke Sand Domschke W. Gastroduodenal Damage due to Drugs, 
Alcohol and Smoking. Clinics in Gastroenterology 1984; 13(2): 405-436. 
113 
Dronfield M.W, Langman M.J.S and Atkinson M. Outcome of endoscopy 
and barium radiography for acute upper gastrointestinal bleeding; Controlled 
trial in 1037 patients. Br. Med. J 1982; 284: 545-548. 
Erickson RA and Glick ME. Why Have Controlled Trials Failed to 
Demonstrate A Benefit of Esophagogastroduodenoscopy in Acute Upper 
Gastrointestinal Bleeding? A Probability Model Analysis. Digestive 
Diseases and Sciences 1986; 31 : 760-768. 
Eastwood G.L. Does the Patient with Upper Gastrointestinal Bleeding 
Benefit from Endoscopy? Reflections and Discussion of Recent Literature. 
Digestive Diseases and Sciences 1981 ; 26 (7): 22s-25s. 
Elta GH. Approach to the patient with gross gastrointestinal bleeding. In: 
Yamada T, David HA, Owyang C,Powell DW., Silverstein FE. (eds). Text 
book of gastroenterology. J. B. Lippincott Company; 1991: 597. 
Friedman GD, Sieglaub AB and Seltzer CC. Cigarettes, alcohol, coffee and 
peptic ulcer. New England Journal of Medicine 1974; 290: 469-473 . 
Friedman LS and Peterson WL. Peptic ulcer and related disorders. In: Fauci, 
Braunwald, Isselbacher et al. eds. Harrison ' s Principles oflnternal Medicine. 
The McGraw-Hill Companies; 1998: 1596 - 1616. 
Gilbert DA, Silverstein FE, Tedesco FJ, et. al.. The National ASGE survey on 
upper gastrointestinal Bleeding: III Endoscopy in upper gastrointestinal 
bleeding. Gastrointestinal Endoscopy 1981 ; 27 (2): 94-102. 
Gostout CJ. Outpatient management of upper gastrointestinal bleeding: Has 
the time finally arrived? Gastrointestinal endoscopy 1998; 47 (3): 311-313. 
Graham DY. Limited value of Early Endoscopy in the Management of acute 
Upper Gastrointestinal Bleeding. Prospective Controlled Trial. Am J. Surg. 
1980; 140: 284-290. 
Graham DY and Smith JL. The course of patients after variceal haemorrhage. 
Gastroenterology 1981 ; 08 (4) : 800-9. 
Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of H. 
pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J 
Gastroenterology 1993 ; 28 : 939-942. 
Gralnek IM, Jensen DM and Kovas TOG. An economic analysis of patients 
with active arterial peptic ulcer haemorrhage treated with active endoscopic 
heater probe, injection sclerosis or surgery in a prospective randomised trial. 
Gastrointestinal Endoscopy 1997; 46 (2): 105-12. 
114 
Griffin MR, Ray WA and Schaffne W. Nonsteroidal Anti-inflammatory Drug 
Use and Death from Peptic Ulcer in Elderly Persons. Annals oflntemal 
Medicine 1988; 109: 359-363. 
Griffiths WJ, Neumann DA and Welsh JD. The visible vessel as an indicator 
of uncontrolled or recurrent gastrointestinal haemorrhage. New Engl J Med. 
1979; 300 (25): 1411-1413. 
Gustavson S, Kelly KA, Melton LJ III and Zinmeister AR. Trends in peptic 
ulcer surgery. A population based study in Rochester, Minnesota, 1956-1985. 
Gastroentorology 1988; 94: 688-94. 
Hasselgren G, Carlsson J, Lind T, Schaffalitzky de Muckadell O and Lundell 
L. Risk factors for rebleeding and fatal outcome in elderly patients with acute 
peptic ulcer bleeding. Eur J of Gastroenterology and Hepatology 1998; 10 
(8): 667-672. 
Hasselgren G, Lind T, Lundell L, Aadland E, Efskind P, Falk A, et al. 
Continuous intravenous infusion of omeprazole in elderly patients with peptic 
ulcer bleeding-results of a placebo-controlled multicentre study. Scand J 
Gastroenterol 1997; 32: 328-333. 
Hay J. A. , Lyubashevsky E, Elashoff J, et. al. Upper Gastrontestinal 
Haemorrhage Clinical Guideline-Determining the Optimal Hospital Length 
of Stay. Am J Med. 1996; 100: 313-322. 
Henry D, Dobson and Turner C. Variability in the Risk of Major 
Gastrointestinal Complications from Nonaspirin Non-steroidal Anti-
inflammatory Drugs. Gastroenterology 1993 ; 105: 1078-1088. 
Henry DA and White I. Endoscopic coagulation for gastrointestinal bleeding. 
New Engl J Med 1988; 318: 186-187. 
Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E and Hautekeete ML. 
Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory 
drugs and aspirin: a case-control study. Gut 1991 ; 32: 730-734. 
Howden CW. Optimizing the pharmacology of acid control in acid related 
disorders. Am J Gastroenterol. 1997; 92: 17s-21s. 
Hudson N, Everitt Sand Hawkey CJ. Inter-observer variation in assessment 
of gastroduodenal lesions associated with non-steroidal anti-inflammatory 
drugs. Gut 1994; 35: 1030-1032. 
Hunt RH: Peptic ulcer disease: Defining the treatment strategies in the era of 
Helicobacter pylori. Am J Gastroenterol. 1997; 92: 36s-43s. 
Imperiale TF and Birgisson S. Somatostatin or Octreotide compared with H2 
antagonists and placebo in the management of acute non-variceal upper 
gastrointestinal haemorrhage: a meta-analysis. Ann Intern Med. 1997; 127: 
1062-71. 
115 
Isenberg JI, Mcquaid KR, Laine Land Rubin W. Acid-Peptic Disorders. In: 
Yamada T, David HA, Owyang C, Powell DW, Silverstein FE. (eds) 
Textbook of Gastroenterology. J. B. Lippincott Company; 1991 : 124 3. 
Ivey KJ. Drugs, Gastritis and Peptic ulcer. J. Clin. Gastroenterology 1981 ; 3 
(Suppl. 2): 29-34. 
Jaeschke R, Guyatt GH, Sackett DL. Users ' guides to the Medical Literature. 
III. How to Use an Article About a Diagnostic Test. B. What are the results 
and will they help me in caring for My Patient? The Evidence-Based 
Medicine Working Group. JAMA 1994; 271 (9) : 703-707. 
Jamieson GG. Current status of indications for surgery in peptic ulcer 
disease. World J Surgery 2000; 24: 256-258. 
Jaramillo JL, Galvez C, Carmona C, Montero JL and Mino G. Prediction of 
Further Haemorrhage in Bleeding Peptic Ulcer. Am J Gastroenterol. 1994; 89 
(12): 2135-2138. 
Jaspersen D, Koerner T, Schorr W, Brennenstuhl M, Raschka C, Harnmat C-
H. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer 
haemorrhage. Gastrointestinal Endoscopy 1995; 41 : 5-7. 
Jenkins SA. Drug Therapy for Non-Variceal Upper Gastrointestinal 
Bleeding: assessment of options. Digestion 1999; 60 (suppl 3): 39-49. 
Jick SS, Perera DR, Walker AM and Jick H. Non-steroidal Anti-
inflammatory Drugs and Hospital Admissions for Perforated Peptic Ulcer. 
Lancet 1987; 2: 380-382. 
Johnson SJ, Jones i>F, Kyle J and Needham CD. Epidemiology and course of 
gastrointestinal haemorrhage in North-east Scotland. Br Med J. 1973; 3: 655-
660. 
Katschinski B, Logan R, Davies J, Faulkner G, Pearson J and Langman M. 
Prognostic factors in upper gastrointestinal bleeding. Dig Dis Sci. 1994; 39: 
706-712. 
Kaufman DW, Kelly JP, Wilholm B-E, Laszlo A, Sheehan JE, Koff RS and 
Shapiro S. The Risk of Acute Major Upper Gastrointestinal Bleeding Among 
Users of Aspirin and Ibuprofen at Various Levels of Alcohol Consumption. 
Am J of Gastroenterol. 1999; 94: 3189 - 3196. 
Kelly JP, Kaufman DW, Koff RS, Laszlo A, Wiholm BE and Shapiro S. 
Alcohol Consumption and the Risk of Major Upper Gastrointestinal Bleeding. 
Am J Gastroenterol. 1995; 90: 1058 - 1067. 
Khuroo MS, Y attoo GN, Javid G et al. A comparison of omeprazole and 
placebo for bleeding peptic ulcer. N Engl J Med 1997; 336: 1054-1058. 
Kollef MH, Canfield DA and Zuckerman GR. Triage considerations for 
patients with acute gastrointestinal haemorrhage admitted to a medical 
intensive care unit. Critical care medicine 1995; 23: 1048-1054. 
116 
Kollef MH, O'Brien JD, Zuckerman GR, Shannon W. BLEED: A 
classification tool to predict outcomes in patients with acute upper and lower 
gastrointestinal haemorrhage. Critical Care Medicine 1997; 25 : 1125-1132. 
Konturek SJ, Kwiechien H, Thulin L, Bielanski Wet. al.. Effects of 
somatostatin-14 and somatostatin-28 on plasma hormonal and gastric 
secretory responses to cephalic and gastrointestinal stimuli in man. Scand J 
Gastroenterol. 1985; 20: 31-8. 
Labenz J and Borsch G. Role of Helicobacter pylori eradication in prevention 
of peptic bleeding relapse. Digestion 1994; 55: 19-23. 
Lai KC, Hui WM, Wong BC, Ching CK, Lam SK. A retrospective and 
prospective study on the safety of discharging selected patients with duodenal 
ulcer bleeding on the same day as endoscopy. Gastrointestinal endoscopy 
1997; 45 (1): 26-29. 
Laine L and Petersen WL. Bleeding Peptic Ulcer. New Engl J Med. 1994; 
3 3 1 : 71 7 -72 7. 
Lanas A, Artal A, Blass JM, Arroyo MT et al. Effect of parental omeprazole 
and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin 
Gastrenterology 1995; 21 : 103-6. 
Laszlo A, Kelly JP, Kaufman DE et. al. Clinical aspects of upper 
gastrointestinal bleeding associated with use of non-steroidal anti-
inflammatory drugs. Am J Gastroenterol. ~998; 93: 721-5. 
Lau JY, Sung JJ, Lam YH et al. Endoscopic re-treatment compared with 
surgery in patients with recurrent bleeding after initial endoscopic control of 
bleeding ulcers. N Engl J Med 1999; 340: 751-756. 
Lau JYW, Sung JJY, Lee KKC, Yung M-Y et al. Effects of intravenous 
omeprazole on recurrent bleeding after endoscopic treatment of bleeding 
peptic ulcers. New Engl J Med 2000; 343 (5): 310-316. 
Levy M, Miller DR, Kaufman DW et.al. Major upper gastrointestinal tract 
bleeding: relation to use of aspirin and other non-narcotic analgesics. Arch 
Intern Med 1988; 148: 281-5 . 
Li MKK, Sung JJY, Woo KS et al. Somatostatin reduces gastric mucosa! 
blood flow in patients with portal hypertensive gastropathy: A randomised, 
double-blind crossover study. Dig Dis Sci 1996; 41: 2440-2446. 
117 
Lin HJ, Lo WC, Lee FY et al. Omeprazole prevents bleeding in peptic ulcer 
patients after endoscopy (abstract). Am J Gastroenterol. 1996; 91: 1918. 
Linegar AG, Knottenbelt JD and Wormald PJ. Accuracy of a portable 
haemoglobinometer in clinical practice. S. Afr Med J. 1991 May 4:79(9): 547-
8. 
Londong W, Angerer M, Kutz K, LandgrafR and Londong V. Diminishing 
efficacy of octreotide (SMS 201-995) on gastric function in healthy subjects 
during one-week administration. Gastroenterology 1989; 96: 713-722. 
Langman MJS and Cooke AR. Gastric and duodenal ulcer and their 
associated diseases. Lancet 1976; 1: 680-683. 
Longstreth GF. Epidemiology of Hospitalisation for Acute Upper 
Gastrointestinal Haemorrhage: A Population-Based Study. Am J 
Gastroenterol. 1995; 90 (2): 206-10. 
Longstreth GF and Feitelberg SP. Outpatient care of selected patients with 
acute non-variceal upper gastrointestinal haemorrhage. Lancet 1995; 345: 
108-111. 
Longstreth GF and Feitelberg SP. Successful outpatient management of acute 
upper gastrointestinal haemorrhage: use of practice guidelines in a large 
patient series. Gastrointest Endosc 1998; 47 : 219-222. 
Maastricht Consensus Report. The European Helicobacter pylori Study 
Group: Current European concepts in the management of Helicobacter pylori 
infection. Gut 1997; 41 : 8-13. 
Macrae FA, St John DJB, Caligiore P et al. Optimal dietary conditions for 
haemoccult test. Gastroenterology 1982; 82: 899-903. 
Macleod IA and Mills PR. Factors identifying the probability of further 
haemorrhage after acute upper gastrointestinal haemorrhage. Br J Surg. 1982; 
69: 256-258. 
Mayberry JF, Penny WJ, Counsell MB and Rhodes J. Mortality in acute 
upper intestinal haemorrhage: a six-year survey from the University Hospital 
of Wales. Postgrad Med J. 1981; 57: 627-632. 
Meilahn JE and Ritchie WP: Bleeding gastric or duodenal ulcer. In: 
Jamieson GG, Debas HT (eds). Surgery of the Upper Gastrointestinal Tract. 
London: Chapman & Hall; 1994: 476-492. 
Mogard MH, Maxwell V, Kovacs T et al. Somatostatin inhibits gastric acid 
secretion after gastric mucosa! prostaglandin synthesis inhibition by 
indomethacin in man. Gut 1985; 26: 1189-1191. 
118 
Mondardini A, Barletti C, Rocca G, Garripoli A, Sambataro A, Perotto C et al. 
Non-variceal upper gastrointestinal bleeding and Forrest's classification: 
diagnostic agreement between endoscopists from the same area. Endoscopy 
1998 Aug; 30(6): 508-12. 
Morgan AG, Clamp SE. OMGE international upper gastrointestinal bleeding 
survey, 1978-1986. Scand J Gastroenterology 1988; 23 (suppl 144): 51-58. 
Morris DL, Hawker PC, Breale yS , et. al. Optimal timing of operation for 
bleeding peptic ulcer: prospective randomised trial. Br Med J (Clin Res) 
1984; 288 (6426) 1277-80. 
Mueller X, Rothenbuehler J-M and Amery A. Outcome of peptic ulcer 
haemorrhage treated according to a defined approach. World J Surg. 1994; 18: 
406-410. 
Northfield TC. Factors Predisposing to Recurrent Haemorrhage after Acute 
Gastrointestinal Bleeding. British Medical J 1971 ; 1: 26-28. 
O' Connor KW, Robinson M, Boyce G. et al. Role of endoscopy in 
management of non-variceal acute upper gastrointestinal bleeding. Guidelines 
for clinical application. Gastrointestinal Endoscopy 1992; 38 (6): 760-764. 
Ohmann C, Imhof Mand Roher HD. Trends in peptic ulcer Bleeding and 
Surgical Treatment. World J. Surg. 2000; 24 (3 ): 284-293 . 
Olsen JA, Loud FB, Christianssen J. Inhibition of meal stimulated gastric 
acid secretion by the octapeptide somatostatin analogue SMS 201-995. Gut 
1987; 28: 464-467. 
Ostensen H, Gudmundsen TE, Ostensen M, Burhol PG and Bonnvie 0 . 
Smoking, Alcohol, Coffee and familial factors : Any Association with Peptic 
Ulcer Disease? Scand J Gastroenterol. 1985; 20: 1227 -1235. 
Palmer KR. Ulcers and Nonvariceal Bleeding. Endoscopy 2000; 32 (2): 118-
123 . 
Panes J, Pique JM, Bordas JM et. al. Effect of bolus injection and continuous 
infusion of somatostatin on gastric perfusion in cirrhotic patients with portal 
hypertensive gastropathy. Hepatology 1994; 20: 336-341. 
Pascu 0 , Draghici A, Acolovchi I. The effect of endoscopic haemostasis with 
alcohol on mortality rate of nonvariceal upper gastrointestinal haemorrhage. A 
randomised prospective study. Endoscopy 1989; 21: 53-5. 
Patchett SE, O' Donoghue DP. Pharmacological manipulation of gastric 
juice: thrombographic assessment and implications for treatment of 
gastrointestinal haemorrhage. Gut 1995; 36: 358-62. 
Peduzzi P, Concato J, Kemper E, Holford TR, and Feinstein AR. A 
Simulation Study of the Number of Events per Variable in Logistic 
Regression Analysis. J Clin Epidemiology 1996; 49, 12: 1373-1379. 
119 
Perng C-L, Lin H-J, Chen C-J, Lee F-Y, Lee S-D and Lee C-H. 
Characteristics of patient with Bleeding Peptic Ulcers Requiring Emergency 
Endoscopy and Aggressive Treatment. Am J Gastroenterol 1994; 89: 1811-
1814. 
Peterson WL and Cook DH. Antisecretory Therapy for Bleeding Peptic 
Ulcer. JAMA 1998; 280 (10): 877-878. 
Petrini JL Jr. Endoscopic therapy for gastrointestinal bleeding. Postgraduate 
Medicine 1988; 84 (2): 239-245. 
Pilotto A, Leandro G, Mario FD, Franceschi M, Bozzola L, Valerio G. Role 
of Helicobacter pylori Infection on Upper gastrointestinal Bleeding in the 
elderly: A Case-Control Study. Dig Dis and Sci. 1997; 42: 586-591. 
Provenzale D, Sandler RS, Wood DR, Levinson SL, Frakes JT et al. 
Development of a scoring system to predict mortality from upper 
gastrointestinal bleeding. Am J Med Sci 1987; 294 (1): 26-32. 
Report of Joint Working Group. Guidelines for good practice in and audit of 
the management of upper gastrointestinal haemorrhage. Report of a Joint 
Working Group of British Society of Gastroenterology, Research Unit of the 
Royal College of Physicians of London and the Audit Unit of the Royal 
College of Surgeons of England. J Royal College of Physicians of London 
1992; 26:281-289. 
Robert Band Martin JB. Faintness, syncope, Dizziness and Vertigo. In: 
Fauci AS. Braunwald E, Isselbacher KJ et al. (eds). Harrisson's Principles of 
Internal medicine. Mcgraw-Hill Companies; 1998: 100-107. 
Rockall TA, Logan RF, Devlin HB et al. for the Steering Committee and 
members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. 
Incidence of and mortality from acute upper gastrointestinal haemorrhage in 
United Kingdom. BMJ 1995; 311 (6999): 222-6. 
Rockall TA, Logan RF A, Devlin HB and Northfield TC. Risk assessment 
after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316-321. 
Rockall TA, Logan RF A, Devlin HB, Northfield TC. Selection of patients for 
early discharge or outpatient care after acute upper gastrointestinal 
haemorrhage. Lancet 1996; 347: 1138-40. 
Rockall TA, Logan RFA, Devlin HB, Northfield TC. Variation in outcome 
after acute upper gastrointestinal haemorrhage. Lancet 1995; 346: 346-50. 
Rockall .TA, Logan RSA, Devlin Hand Northfield TC. Incidence of and 
mortality from acute upper gastrointestinal haemorrhage in the U.K. BMJ 
1995: 311: 222-6. 
120 
Rockey DC, Auslander A, Greenberg PD. Detection of Upper 
Gastrointestinal Blood with Faecal Occult Blood Tests. Am J Gastroenterol. 
1999; 94: 344-350. 
Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication 
of Helicobacter pylori reduces the possibility of re bleeding in peptic ulcer 
disease. Gastrointestinal endoscopy 1995; 41: 1-4. 
Rollhauser C and Fleischer DE. Nonvariceal upper gastrointestinal bleeding: 
An update. Endoscopy 1997; 29: 91-105. 
Rutgeerts P, V antrappen G, Broeckaert L. Comparison of endoscopic 
polidocanol injection and YAG laser therapy for bleeding peptic ulcers. 
Lancet 1989; 1: 1164-7. 
Sanderson JD, Taylor RF, Pugh Sand Vicary FR. Specialised gastrointestinal 
units for the management of upper gastrointestinal haemorrhage. Postgrad Med J 
1990; 66: 654-656. 
Santander C, Gravalos RG, Gomez-Cedenill A, Cantero J, Pajares JM. 
Antimicrobial therapy for Helicobacter pylori infection versus long-term 
maintenance anti-secretion treatment in the prevention of recurrent 
haemorrhage from peptic ulcer. Prospective non-randomised trial on 125 
patients. Am J Gastroenterol 1996; 91 : 1549-1552. 
Schaffalitzky de Muckadell OB, Havelund T, Harling H, Boesby S, Snel P, 
Vreeburg EM et al. Effect of omeprazole on outcome of endoscopically 
treated bleeding peptic ulcers-randomised double blind placebo-controlled 
multicentre study. Scand J Gastroenterol 1997; 32 (4): 320-327. 
Schiller KF, Truelove SC, and Williams DG. Haematemesis and Melaena, 
with Special Reference to Factors Influencing the Outcome. Br Med J 1970; 
4 April : 7-14. 
Schuckit MA: Alcohol and alcoholism. In: Fauci A.S. Braunwald E, 
Isselbacher KJ et al. (eds). Harrisson ' s Principles oflntemal medicine, 14th 
ed. Mcgraw-Hill Companies; 1998: 2503-2508. 
Segal I, Solomon A. Tim LO et al. The Giant Duodenal Ulcer Syndrome. S 
Afr Med J. 1977; 52: 724-727. 
Shields R. Bleeding oesophageal varices. In: Gilmore IT. and Shields R 
(eds). Gastrointestinal Emergencies W.B. Saunders Company; 1992: 60-73 . 
121 
Silverstein F.C. Gilbert D.A., Tedesco F.J, Buenger N.K, Persing J and 
members of the ASGE survey on upper Gastrointestinal bleeding II : Clinical 
prognostic factors. Gastrointestinal Endoscopy 1981; 27 (2): 80-93 . 
Simel L D., Samsa P.G and Matchar D.B. Likelihood Ratios with Confidence: 
Sample Size Estimation for Diagnostic Test Studies. J Clin Epidemiol 1991 ; 
44 (8): 763-770. 
Somerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory 
drugs and bleeding peptic ulcer. Lancet 1986; 1: 462-4. 
Somerville KW, Davies JG, Hawkey CJ, Henry DA et al. Somatostatin in 
treatment ofhaematemesis and melaena. Lancet 1985; 1: 130-132. 
Steffes C and Fromm D. The current diagnosis and management of upper 
gastrointestinal bleeding. Advances in Surgery 1992; 25: 331-361. 
Steffes CP and Sugawa C. Endoscopic management ofNon-variceal 
gastrointestinal bleeding. World J. of Surgery 1992; 16: 1025-1033. 
Storey DW, Bown SG, Swain CP ,Salmon PR et.al. Endoscopic prediction of 
recurrent bleeding in peptic ulcers. New Engl. J Med. 1981; 305 : 915-6. 
Sugawa C, Steffes CP, Nakamura R, Sferra JJ et al. Upper GI bleeding in an 
Urban Hospital: Etiology, Recurrence, and Prognosis. Ann. Surg. 1990; 212: 
521-527. 
Sugawa C, Benishek D and Walt AJ. Mallory-Weiss syndrome: A study of 
224 patients. Am J Surg. 1983; 145 (1): 30-33. 
Terdiman JP and Ostroff JW. Risk of persistent or Recurrent and Intractable 
Upper Gastrointestinal Bleeding in the Era of Therapeutic Endoscopy. Am J 
Gastroenterol. 1997; 92: 1805-1811. 
Terdiman JP. Update on upper gastrointestinal bleeding. Basing treatment 
decisions on patients' risk level. Postgraduate Medicine 1998; 103 (6): 43-64. 
Tulassay Z, Gupta R, Papp J, Bodnar A. Somatostatin versus cimetidine in 
the treatment of actively bleeding duodenal ulcer: A prospective, randomised, 
controlled trial. Am J Gastroenterol. 1989; 84: 6-9. 
Turner IB, Jones Mand Piper DW. Factors Influencing Mortality from 
Bleeding Peptic Ulcers. Scand. J. Gastroenterol. 1991; 26: 661- 666. 
Tygat GNJ, Noach LA, Rauws EAJ: Helicobacter pylori infection and 
duodenal ulcer disease. Gastroenterol Clin North Am. 1993; 22: 127-139. 
Tytgat GNJ. Treatment of Peptic Ulcer. Digestion 1998; 59: 446-452. 
Tytgat GNJ. Ulcers and Gastritis. Endoscopy 2000; 32 (2): 108-117. 
122 
Van Stiegmann G, Bornman PC, Terblanche J and Marks IN. Bleeding Peptic 
Ulcer-With Special Reference to High-Risk Groups of patients. Surg. 
Gastroenterol. 1983; 2: 245-251. 
Villanueva C, Balanzo J, Espinos JC. Prediction of therapeutic failure in 
patients with bleeding peptic ulcer treated with endoscopic injection. Dig. 
Dis. Sci 1993; 38: 2062-70. 
Villanueva C, Balanzo J, Sabat Met al. Injection therapy alone or with 
endoscopic haemoclip for bleeding peptic ulcer: preliminary study of a 
randomised trial (abstract). Gastrointestinal Endoscopy -19_96; 43: 361. 
Villanueva C, Balanzo J, Torras X et. al. Omeprazole versus ranitidine as 
adjuvant therapy to endoscopic injection in actively bleeding ulcers. A 
prospective and randomized study. Endoscopy 1995; 27: 308-12. 
Wallace J L. How do NSAIDs cause ulcer disease? Balliere's Clinical 
Gastroenterology 2000: 14 (1): 147-159. 
Wara P and Stodkilde H. Bleeding pattern before admission as a Guide for 
Emergency Endoscopy. Scand. J Gastroenterol. 1985; 20: 72-78. 
Wara P, Berg V, Amdrup E. Factors influencing mortality in patients with 
bleeding ulcer. Acta Chir Scand. 1983; 149: 775-785. 
Wara P, Host V, and Stodkilder H. Clinical Factors Predisposing to Major 
Ulcer Bleeding. A Logistic Regression Analysis. Acta Chir Scand. 1985; 
151: 349-354. 
Wara P. Endoscopic prediction of major re bleeding - a prospective study of 
stigmata of haemorrhage in bleeding ulcers. Gastroenterology 1985; 88: 
1209-14. 
Wara P. Incidence, Diagnosis and Natural course of upper gastrointestinal 
haemorrhage. Prognostic Value of Clinical Factors and Endoscopy. Scand. J. 
Gastroenterol 1987; 22 (suppl. 137): 26-27. 
Wasson JH, Sox HC, Neff RK, Goldman L. Clinical Prediction Rules. 
Application of methodological standards. NEJM 1985; 313: 793-9. 
Weil J, Colin-Jones D, Langman Met al. Prophylactic aspirin and risk of 
peptic ulcer bleeding. Br Med J. 1995; 310: 827-30. 
Whigham TE. Gastrointestinal bleeding. In Brady III CE (ed.) Contemporary 
Management in Internal Medicine Vol 1 (3). Oesophagus/Stomach/GI 
Bleeding. Churchill Livingstone Publication; 1991: 179-203. 
123 
Whitehouse I, Beglinger C, Ruettimann C, Gyr K. Inhibition of pentagastrin-
stimulated acid secretion after subcutaneous administration of a new 
somatostatin analogue. Gut 1986; 27: 141-146. 
Zimmerman J, Siguencia J, Tsvang E, Beri Rand Amon R. Predictors of 
Mortality in Patients Admitted to Hospital for Acute Upper Gastrointestinal 
Haemorrhage. Scand J Gastroenterol. 1995; 30: 327-331. 
APPENDIX A 1 
UPPER GASTROINTESTINAL BLEEDING AUDIT 
(1) Study no (3) Ward ..._! --....J 
(2) Date ! t9 Address: 
dd mm yy 
Label or Surname: 
First 
Folder no 
DOB I 119 
CLINICAL DIAGNOSIS/CONDITION: 
Upper GI Bleed: 
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1. Bleeding . 
(4) duration of bleed that 
caused patient to present 
(5) melaena 
( 6) haematemesis 














(other than 5, 6 























4. Underlying conditions 
( 16) cardiac 
( 1 7) pulmonary 







*To be filled in before discharge 
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>24-48 hrs >48-72 hrs 
yes 
yes 
<72 hrs 72 hrs to 
7 days 
I 





details (soecifv drue: and dose) 





APPENDIX A 4 
4. Underlying conditions continued comment 
( 19) hepatic · no yes 
(20) haematological no yes 
(21) alcoholism no yes 
(chronic) 
(22) other no yes 
5. Examination 
(23) lymph nodes (incl 
Virchow-Trossier) 
(24) telangiectasis 
(25) Hb % 
(26) pulse 
(27) BP I ----
supine 
(28) BP I ----
sitting 
(29) BP I cannot be done ----
standing specify reason: 
(30) abdomen NAO tender mass visceromegaly 
(31) vomit NAO fresh coffee both no sample 
blood grounds 
(32) stool NAO fresh melaena both no sample 
blood 
(33) occult blood -ve +ve no stool on PR 
(34) Cardiovascular Sys tern NAD abnormal 
(35) CNS NAD abnormal 
(36) Musculoskeletal NAD abnormal 
System 
(3 7) Respiratory System NAD abnormal 
C:GENERAL\UGIBFIN.DOC 
APPENDIX A 
6. Haemoglobin status 
(3 8) Hb on admission 
*(39) Hb drop(after admission) no yes 
* ( 40) transfusion requirements units 
7. Assessment 
( 41) insignificant bleed admit if discharged, comment: 
significant bleed admit if discharged, comment: 
NB If discharged arrange OPD scope 
8. Assessment of endoscopy tim · mg 
( 42) Endoscopy appointment emergency routine urgent(next list) 
9. Clinical Diagnosis by assessing doctor 
Cause of UGIB comment 
( 43) var1ces no yes 
(44) Mallory -Weiss no yes 
(45) oesophagitis no yes 
(46) gastritis no yes 
(47) peptic ulcer no yes 
(48) Ca no yes 
(49) other no yes 
(50) unknown no yes 
10. 
(51) 
If endoscopy was unavailable on site I would 
or 
Treat empirically I 
Transfer for endoscopy ================== 






FOR THE ENDOSCOPIST 
11. Endoscopy 
(52) Source of bleed 
identified 
(53) stigmata of recent 
haemorrhage 
12. Diagnosis at Endoscopy 
(54) vances 
(55) Mallory -Weiss 
(56) oesophagi tis 
(57) gastritis 











































(68) H pylori 
hist status 










17. Date of Discharge 
Date 
(71 ). -1 -....------.-, -19---, 
dd mm yy 
18. Status at one month 
Date 
(72). -1 -----,-19---
dd mm yy 




malignant not done 
-ve +ve not done 
-ve +ve not done 
yes 
under-running 
under-running with Hp eradication 
definitive 
died died unknown 
(related) (unrelated) 
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UPPER GASTROINTESTINAL BLEEDING AUDIT 














I I I I I 
D M M y 
I I I I I 
D M M y 
Date of I I I I I I 
y 
y 
Birth: D D M M Y Y 




1 . Marita I status: L---1 M,;_a,;_r_ri..:....ed,;_____._l ...::S_.;.i n~g~le,;__....1..I _D_iv_o_rc_;.e,;_d_.i_l W,;__id...::o_w....:..e,;_d __.j,;_S:....;e_._p_a r_a..:....te:....:..d__J 
2. Source of income: 
3. How do you rate your health? ._! E_x_c_e_lle_n_t __.j_G_o_o_d _ ___._j _F_a_ir __ ........ l _P_oo_r _ 
4. Did you have repeat endoscopy? I Yes I No 
5. Status at one month 
Resolved Rebleed Died Died Unknown 
Related Unrelated 
Comment: 
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